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Introduction 
 1
1 INTRODUCTION 
1.1 Acute myeloid leukemia  
 Acute myeloid leukemia (AML), is characterized by the uncontrolled proliferation of 
malignant hematopoietic precursor cells which accumulate in the bone marrow and interfere 
with normal hematopoiesis. AML is the most common acute leukemia affecting adults, 80 to 
85% of cases of acute leukemia diagnosed in individuals over the age of 20 years. AML is a 
relatively rare disease overall (1-2 cases/100,000), its incidence is expected to increase as the 
population ages (Schoch et al., 2001). 
 
1.1.1 Pathophysiology and classification of AML 
AML is caused by a block of differentiation at the state of myeloblast. The differentiation 
block is caused by accumulation of genetic changes (mutations) in the genes controlling the 
differentiation and cell proliferation. The clinical signs and symptoms of AML result from the 
fact that, as the leukemic clone of cells grows, it tends to displace or interfere with the 
development of normal blood cells in the bone marrow. This leads to neutropenia, anemia, 
and thrombocytopenia. The clinical symptoms of AML are in turn often due to the low 
numbers of these normal blood elements.  
 
Much of the diversity and heterogeneity of AML stems from the fact that leukemic 
transformation can occur at different stages of differentiation pathway. The two most 
commonly used classification schemes for AML, are the older French-American-British 
(FAB) system and the newer World Health Organization (WHO) system. 
 
French-American-British Classification: 
The French-American-British (FAB) classification system was proposed in 1976 (Bennett et 
al., 1976) and divides AML into 8 subtypes, M0-M7 (Table 1), based on the type of cell from 
which the leukemia developed and its degree of maturity. This is done by examining the 
appearance of the malignant cells under light microscopy and/or by using cytogenetics to 
characterize any underlying chromosomal abnormalities. The subtypes have varying 
prognoses and responses to therapy. 
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Table 1.1.1: French-American-British classification of AML 
 
World Health Organization classification 
The World Health Organization (WHO) classification of acute myeloid leukemia (AML) 
attempts to be more clinically useful and to produce more meaningful prognostic information 
than the FAB criteria. The WHO classification designates a patient into the category of AML 
if the patients have 20% or above myeloblasts. The WHO subtypes of AML are 
AML with characteristic genetic abnormalities, which includes AML with translocations 
between chromosome 8 and 21 [t(8;21)], inversions in chromosome 16 [inv(16)], or 
translocations between chromosome 15 and 17 [t(15;17)]. Patients with AML in this category 
generally have a high rate of remission and a better prognosis compared to other types of 
AML.  
AML with multilineage dysplasia. This category includes patients who have had a prior 
myelodysplastic syndrome (MDS) or myeloproliferative disease (MPD) that transforms into 
AML. This category of AML occurs most often in elderly patients and often has a worse 
prognosis.  
AML and MDS, therapy-related. This category includes patients who have had prior 
chemotherapy and/or radiation and subsequently develop AML or MDS. These leukemias 
Introduction 
 3
may be characterized by specific chromosomal abnormalities, and often carry a worse 
prognosis.  
AML not otherwise categorized. Includes subtypes of AML that do not fall into the above 
categories.  
Acute leukemias of ambiguous lineage. Acute leukemias of ambiguous lineage (also known as 
mixed phenotype or biphenotypic acute leukemia) occur when the leukemic cells can not be 
classified as either myeloid or lymphoid cells, or where both types of cells are present.  
  
1.2 Two-Hit model of AML 
AML is not caused by a single genetic alteration, but it requires a minimum of two genetic 
alterations for the preleukemia to develop into AML. This hypothesis is called the two-hit 
model of AML, based on the studies carried out in mouse models with genetic alterations 
found in patients with AML (Grisolano et al., 1997; He et al., 1997; Kelly et al., 2002a; 
Schessl et al., 2005). The model hypothesizes that there are two classes of mutations that are 
required for development of AML; (i) Class I mutations which involves the mutations in the 
genes responsible for cell proliferation leading to survival and proliferative advantage to the 
cells. This class includes genes such as FLT3, RAS, c-KIT etc. (Figure 1.2). (ii) Class II 
mutation involves the mutations in the genes responsible for the differentiation. These 
mutations block the differentiation and apoptosis of cells, examples of this class are the 
chromosomal translocations like AML1/ETO, PML/RARa, inv(16) etc. or transcription 
factors like C/EBP alpha or p53 (Figure 1.2). 
 
In support of this hypothesis, FLT3 mutations frequently occur in considering with other gene 
rearrangements and point mutations. For example, FLT3-ITDs have been reported in patients 
with t(8;21), inv(16), t(15;17), 11q23 gene rearrangements involving mixed lineage leukemia 
(MLL) gene, and MLL internal tandem duplications (Jamal et al., 2001; Kiyoi et al., 1997; 
Kottaridis et al., 2001; Nomdedeu et al., 2001; Thiede et al., 2002). 
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Figure1.2: Two-Hit model for AML: The model states that two classes of mutations of are required for 
development of AML; class I mutations that confers proliferative advantage to cells and class II mutation that 
blocks differentiation.  
 
1.3 Receptor tyrosine kinases 
The extracellular signal proteins that act through receptor tyrosine kinases consist of a large 
variety of secreted growth factors and hormones. The human genome as currently sequenced, 
is thought to contain 90 tyrosine kinase genes, of which 58 are of the receptor type. Receptor 
tyrosine kinases can be classified into more than 20 structural families, each dedicated to its 
complementary family of protein ligands. One such family is the Class III receptor tyrosine 
kinases, members of which have been have been found to be mutated or overexpressed in the 
patients with AML. This class includes FMS, KIT, FLT3, PDGFRα and PDGFRβ (Blume-
Jensen and Hunter, 2001). All the members of this class have an extracellular five-fold 
immunoglobulin like domain, a transmembrane, and cytoplasmic juxtamebrane and tyrosine 
kinase domain.  
 
 
 
FLT3 
FLT3 D835V/Y/H 
FLT3-JM-PM 
PML/RARα 
AML1/ETO 
CBFβ/SHMMC
Class I Mutations Class II Mutations 
Confer proliferation/Survival 
Advantage, but do not affect  
differentiation  
AML
Impair differentiation 
and apoptosis 
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1.3.1 Class III receptor tyrosine kinases: role in leukemogenesis  
All the class III RTKs play an important role in normal hematopoiesis with the exception of 
PDGFR. FMS, the receptor for the macrophage colony-stimulating factor (M-CSF), is crucial 
for the growth and differentiation of the monocyte-macrophage-osteoclast lineage (Sherr, 
1990). FLT3 and KIT are both required for the survival, proliferation and differentiation of 
hematopoietic progenitor cells, while c-kit is also important for the growth of mast cells, 
melanocytes, primordial germ cells and interstitial cells of Cajal (Drexler, 1996; Lyman and 
Jacobsen, 1998). The hematopoietic functions of PDGFRβ are less well defined, although the 
receptor and its ligand probably play a significant role in megakaryopoiesis (Yang et al., 
1997). 
 
The class III RTKs have recently been linked to the pathogenesis of an increasing number of 
hematological malignancies. KIT mutations, for example, have been shown to be causative in 
adult-type mastocytosis, as well as being associated with acute myeloid leukaemia and 
sinonasal lymphomas. (Longley et al., 2001), have proposed a classification of mast cell 
disease based on the nature of the c-kit mutations. A recent study has implicated the PDGFR 
alpha mutations in childhood AML, which generally is not expressed in hematopoietic cells 
(Hiwatari et al., 2005).  The role of PDGFRβ-fusion genes in bcr-abl-negative chronic 
myeloproliferative disorders is still unfolding, but at least eight partner genes have been 
identified. FLT3 is a gene most commonly mutated in AML and the presence of FLT3-ITD is 
a strong independent prognostic factor (Kiyoi et al., 1999; Nakano et al., 1999). 
 
1.4 Fms-like Tyrosine kinase (FLT3) 
The FLT3 (also known as fetal liver kinase 2, Flk2) gene is located on chromosome 13q12, 
and and encodes an RTK of 993 amino acids in length. Two isoforms of human FLT3 are 
reported; the glycosylated 158–160-kDa membrane-bound protein and an cytoplasmic 
unglycosylated 130–143- KDa. 
 
 FLT3 plays an important in role in proliferation, differentiation and apoptosis of normal 
hematopoietic cells. In normal cells, expression of FLT3 occurs mainly in early myeloid and 
lymphoid progenitors (Rosnet et al., 1996), and not in erythroid cells (Gabbianelli et al., 
1995), megakaryocytes (Ratajczak et al., 1996) or mast cells (Hjertson et al., 1996). Since 
FLT3 belongs to RTKs, its activation and signalling occurs in the same manner as the other 
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RTKs. In all cases of RTKs, the binding of the signal protein to the ligand-binding domain on 
the outside of the cell activates the intracellular tyrosine kinase domain (Figure 2). Upon 
binding of ligand, transphosphorylation of the selected tyrosine side chains of TKD happens. 
The tyrosine phosphorylated receptor serves as a docking site for an array of intracellular 
signalling molecules, including the GTPase-activating protein (GAP), the p85 subunit of 
phosphatidyl-inositol 3’-kinase (PI3K), phospholipase C-ץ (PLC-ץ), the protein tyrosine 
phosphatase SHP1, Grb2 and Src-like non-receptor kinase (Rosnet et al., 1996). These 
activated proteins then initiate serine/threonine phosphorylation cascades resulting in 
activation of transcription factors that determine a variety of cell responses, including cell 
maintenance, mitogenesis, migration and differentiation (Claesson-Welsh, 1994). Activation 
of FLT3 happens upon the binding of Flt3 ligand (FL), which leads to downstream signalling 
and promotes growth of early progenitor cells (Ray et al., 1996; Rusten et al., 1996; Veiby et 
al., 1996). 
 
 
 
 
 
 
Figure 1.4: Protein tyrosine kinase activation mechanisms; Left: inactive conformation of RPTK. Right: 
ligand-induced receptor dimerization and tyrosine autophosphorylation  (From P. Blume-Jensen and T. Hunter, 
Nature 411:355-365, 2001). 
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1.4.1 FLT3 crystal structure 
Griffith et al., 2004, crystallised the inactive or unphosphorylated form of the cytoplasmidc 
domain of FLT3. The principal features of the autoinhibited FLT3 structure include the 
bilobal kinase fold, the activation loop, and the JM domain (Figure 1.4.1). The kinase fold in 
FLT3 is that typically found in most protein kinases and consists of N- and C-terminal 
domains (N and C lobes) (Knighton et al., 1991). Kinase N and C lobes are typically 
connected by a single flexible polypeptide stretch that allows considerable rotational 
movement of the two domains relative to each other. This conformational diversity is 
observed in the multitude of available kinase structures (Huse and Kuriyan, 2002). When the 
N lobe is rotated away from the C-terminal domain, the kinase is in the catalytically 
“inactive” form. Conversely, if the N lobe is rotated toward the C lobe, allowing key catalytic 
residues from both lobes to align, the kinase adopts the catalytically “active” conformation. 
The crystal structure of autoinhibited FLT3 conforms to the prototypical conformation 
common to other inactive kinases that have a “closed” activation loop folded between the two 
lobes of the inactive kinase fold. Activation of FLT3 requires at least phosphorylation of the 
three tyrosines residues in the activation loop. When these tyrosines are unphosphorylated, the 
activation loop of FLT3, typically assumes the closed conformation blocking access to the 
peptide substrate and ATP binding sites.  
 
 
 
Figure 1.4.1: Crystal structure of inactive conformation of intracellular FLT3 protein (' protein data bank 
(PDB) accession No:' 1RJB). ' space fill; (A) and ' Ribbon ' (B) model of the JM domain and TKD. The JM 
domain (green) with the three regions JM-B, JM-S and JM-Z as well as the TKD is shown consisting of ' N lobe ' 
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(yellow), ' C lobe ' (blue) and the activation loop (light blue). The JM domain is the most important 
autoinhibitory element of the inactive FLT3-Kinase. (Figure taken from the thesis of Dr. Carola Reindl, 
University hospital, University of Munich, Germany). 
 
A distinct feature of the FLT3 structure is the presence of a Juxtamembrane domain that 
adopts its autoinhibited conformation and interacts with all key features of FLT3. 
Topologically the JM can be divided into three parts: the JM binding motif (JM-B), the JM 
switch motif (JM-S), and the zipper or linker peptide segment (JM-Z). The JM binding motif 
(JM-B), acts as a autoinhibitory domain, by preventing the rotation of N lobe towards the C 
lobe of the tyrosine kinase domain (TKD) to generate the activated kinase fold. The JM 
switch motif (JM-S) that lies next to JM-B provides a rigid and properly oriented framework 
for the interposition of tyrosines 589 and 591 between the JM-S and the C lobe of the kinase. 
 
 
1.4.2 FLT3 mutations in AML 
FLT3 is expressed at high levels in a spectrum of hematologic malignancies including 70% to 
100% of acute myelogenous leukemia (AML) of all FAB subtypes, B-precursor cell acute 
lymphoblastic leukemia (ALL), a fraction of T-cell ALL, and chronic myelogenous leukemia 
(CML) in lymphoid blast crisis. These data indicate that FLT3 expression may play a role in 
the survival or proliferation of leukemic blasts (Carow et al., 1996; Drexler, 1996). Both 
FLT3 overexpression and activating mutations in the FLT3 gene can be found in patients with 
AML. Three  distinct activating mutations of FLT3 in haematological malignancies have been 
reported: point mutations (FLT3-JM-PM) and FLT3-internal tandem duplications (FLT3-
ITD) found in the JM domain are present in 2% and 20-25%  of AML patients respectively, 
whereas, mutations in the tyrosine-kinase domain (FLT3-TKD) represent 7-10% of AML 
patients (Figure 1.4.2) (Abu-Duhier et al., 2001; Abu-Duhier et al., 2000; Kindler et al., 2005; 
Kottaridis et al., 2001; Reindl et al., 2006; Stirewalt et al., 2004; Thiede et al., 2002; 
Yamamoto et al., 2001).  
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Figure 1.4.2: Flt3 activating mutations found in AML patients: FLT3-ITD and FLT3-JM-PM mutations are 
found in the juxtamembrane, where as FLT3-TKD mutations are found in the tyrosine kinase domain of FLT3. 
 
1.4.3 FLT3-Internal tandem duplications 
Recent advances in genetics have shown that not only chromosome abnormalities but also 
molecular alterations are useful to characterize and subclassify acute myeloid leukemia 
(AML). For example, partial tandem duplication within the MLL gene (MLL-PTD) has been 
shown to define a subgroup of AML patients with unfavourable clinical outcome (Schnittger 
et al., 2000). FT3-ITDs are another class of muations which defines a poor prognostic 
subgroup in the AML patients.  
 
FLT3-ITD have been detected in all FAB subtypes of AML, with the highest reported 
frequency in the M3 and M5 subtype, and less frequently in the M2 subtype. FLT3-ITD are 
associated with leukocytosis and poor prognosis in most, (Kiyoi et al., 1999; Rombouts et al., 
2000; Thiede et al., 2002; Whitman et al., 2001; Xu et al., 1999; Yamamoto et al., 2001) 
except few studies (Schnittger et al., 2002; Thiede et al., 2002). Recent data indicate that 
FLT3-ITD is not present in systemic mast cell disease or in a spectrum of solid tumors. In 
addition to length mutations in one allele of FLT3 several studies have demonstrated biallelic 
mutations in FLT3, as well as patients in whom the residual wild-type allele is lost (Kottaridis 
et al., 2001; Schnittger et al., 2002; Thiede et al., 2002; Whitman et al., 2001).  
 
FLT3-ITD
20-25% 
Internal tandem duplication: 
FLT3-TKD
7-10% 
FLT3-JM-PM
1-2% 
Juxtamembrane point mutants 
Tyrosine kinase point mutations/ insertions 
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FLT3-ITDs are in-frame duplications of a fragment of the JM domain. FLT3-ITDs are highly 
heterogeneous and vary in length from 2 to 68 AA. These duplications are thought to disrupt 
the autoinhibitory mechanism of FLT3 and result in constitutive activation of the tyrosine 
kinase function of FLT3. Recent studies have shown that FLT3-ITDs are found in the 
leukemic stem cells of the AML patients (Levis et al., 2005). The presence of an FLT3-ITD 
has been recognized as an independent poor prognostic factor in AML and is associated with 
a decreased survival due to an increased relapse rate (Boissel et al., 2002; Kiyoi et al., 1999; 
Kottaridis et al., 2001; Moreno et al., 2003; Pollard et al., 2006; Preudhomme et al., 2002; 
Schnittger et al., 2002; Thiede et al., 2002). Several factors influence the poor prognosis seen 
in AML patients harboring the FLT3-ITDs, e.g., a high FLT3-ITD/wild type ratio is one of 
the reasons for poor prognosis in AML patients.(Thiede et al., 2002; Whitman et al., 2001) A 
recent study has reported that the detection of FLT3-ITD mutation in less mature progenitor 
populations, e.g. CD34+/CD33-, might be associated with disease resistance (Pollard et al., 
2006). 
 
FLT3-ITDs constructs are constitutively autophosphorylated on tyrosine residues, causing 
activation of signal transducer and activator of transcription (STAT5) and mitogen-activated 
protein (MAP) kinases and AKT (Brandts et al., 2005; Hayakawa et al., 2000; Mizuki et al., 
2000; Spiekermann et al., 2003; Tse et al., 2000; Tse et al., 2001). In addition, transduction of 
FLT3-ITD and TKD mutants in murine IL-3-dependent cell lines, such as Ba/F3 and 32D 
induces IL-3 independent growth (Hayakawa et al., 2000; Tse et al., 2000) in vitro. 32D or 
Ba/F3 cells stably transfected with constitutively activated FLT3 when injected into syngeneic 
recipient mice results in the development of a leukemic phenotype (Mizuki et al., 2000). 
Furthermore, retroviral transduction of FLT3-ITD constructs in primary murine bone marrow 
cells induces in a myeloproliferative phenotype in a mouse bone marrow transplantant model 
(Kelly et al., 2002a). These data demonstrate that, although FLT3-ITDs have been associated 
primarily with AML in humans, FLT3-ITD alone is not sufficient to induce AML in primary 
hematopoietic cells. Furthermore, a kinase-dead mutant of FLT3 in the context of FLT3-ITD 
abrogates the myeloproliferative disease, indicating an absolute requirement of FLT3 kinase 
activity for the myeloproliferative phenotype in this model. No difference in biologic activity 
of FLT3-ITD mutants have been found in cell culture or murine models, despite considerable 
variation in repeat length that ranges from several to more than 50 amino acids.  
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Thus, FLT3-ITDs mutations in the FLT3 gene result in constitutive activation of the kinase 
activity and downstream targets including STAT5, RAS/MAPK, and PI3K/AKT.  
 
1.5 RTK inhibitors 
Although activating FLT3 mutations are not sufficient to cause an AML phenotype they 
represent a potential therapeutical target. Targeted inhibition of aberrant kinase signalling can 
be an effective therapeutic intervention in hematologic malignancies, as evidenced by 
hematologic and cytogenetic responses in chronic myelogenous leukemia (CML) and CML 
blast crisis patients treated with the BCR-ABL kinase inhibitor imatinib mesylat (STI571, 
Gleevec®) (Druker et al., 2001a; Druker et al., 2001b). An analogous kinase inhibitor strategy 
might have therapeutical potential in AML patients with activating mutations in the FLT3 
gene.  
 
 In the past decade, many laboratories embarked on projects aimed at generating compounds 
that specifically inhibit the activity of the signalling cascades triggered by tyrosine kinases. 
Compounds with selective activity to class III RTK in vitro include AG1295 (Levis et al., 
2001), SU5416 (Fong et al., 1999; O'Farrell et al., 2004; Spiekermann et al., 2003; 
Spiekermann et al., 2002), SU11248 (Yee et al., 2004) and CT53518 (Kelly et al., 2002b). 
Three compounds (CEP-701, SU11248 and PKC412) with in vivo activity are currently being 
evaluated in phase I/II clinical trials in patients with AML and have shown promising results 
(O'Farrell et al., 2003a; O'Farrell et al., 2003b; Smith et al., 2004).  
 
PKC412 (Novartis), an inhibitor initially discovered as an inhibitor of protein kinase C, was 
found to block the phosphorylation and activity of FLT3-WT and mutant FLT3-receptors 
(Stone et al., 2005; Weisberg et al., 2002). This inhibitor blocks the FLT3 kinase activity 
thereby inducing apoptosis in FLT3-expressing cell lines and cause cytotoxicity in primary 
ALL and AML blasts (Spiekermann et al., 2003; Tse et al., 2001) 
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2 AIM OF THE STUDY 
Activating mutations in the juxtamembrane domain of FLT3 (FLT3-ITDs, internal tandem 
duplications) represent the most frequent genetic alterations in acute myeloid leukemia and 
define a distinct molecular entity in AML. FLT3-internal tandem duplications (FLT3-ITDs) 
are a heterogenous group of mutations in patients with acute leukemias that are prognostically 
important. Crystal structure of the inactive FLT3-WT has shown that the juxtamambrane 
domain acts as an autoinhibitory domain and two tyrosine residues 589 and 591 has been 
postulated as possible phosphorylation sites. No study so far has looked for any common 
signature in the FLT3-ITDs or the role of tyrosine residues in juxtamembrane  on FLT3-ITDs. 
Hence we wanted to study the role of the Juxtamabrane domain of FLT3-ITDs in two 
directions. 
1. To look for a common motif in juxtamembrane domain that is duplicated in all the 
patients harboring FLT3-ITDs and influences the transforming potential of FLT3-
ITDs. 
2. To look for the role of tyrosine residues in the juxtamebrane domain on the 
transforming potential of the FLT3-ITDs 
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3 MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Antibodies 
Primary antibodies 
α-AKT (#9272)   Rabbit, polyclonal  Cell signalling, NEB Frankfurt  
α-FLT3 (S18, sc-480) Rabbit, polyclonal  Santa Cruz, CA, USA 
α-FLT3 (C20, sc-479)  Rabbit, polyclonal   Santa Cruz, CA, USA 
α-p44/42MAP-Kinase Rabbit, polyclonal  Cell Signaling, NEB, Frankfurt 
(#9102) 
α-STAT5 (C17, sc-835) Rabbit, polyclonal   Santa Cruz, CA, USA 
normal IgG (sc-2027)  Rabbit    Santa Cruz, CA, USA 
normal IgG (sc-2025)  Mouse    Santa Cruz, CA, USA 
 
Phosphospecific primary antibodies 
α-pTyr(PY99) (sc-7020)  Mouse, Monoclonal   Santa Cruz, CA, USA 
α-pSTAT5 (Tyr-694)  Rabbit, polyclonal  Cell Signaling, NEB, Frankfurt 
(#9351) 
α-p44/p42 MAP Kinase Rabbit, polyclonal  Cell Signaling, NEB, Frankfurt 
(#9101) 
α-pAKT (Ser473) (#9271) Rabbit, polyclonal  Cell Signaling, NEB, Frankfurt 
 
Secondary antibodies 
α-Mouse IgG-HRP conjugated    Santa Cruz, CA, USA 
α-Rabbit IgG-HRP conjugated     Sigma, Taufkirchen 
 
FACS antibodies 
CD135-PE IgG1 (2234) Mouse    Immunotech, Marseille, France 
IgG1-PE contol (A07796) Mouse    Immunotech, Marseille, France 
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3.1.2 Plasmids 
Retroviral expression Vector 
pMSCV-eYFP-IRES (MIY)  A murine stem cell virus vector containing and 
IRES site and YFP Tag, was kindly provided by 
Dr.  R. K. Humphries (Terry Fox Laboratory, 
Vancouver, Canada)                   
 
RTK Plasmid constructs 
MIY-FLT3-WT  Prepared in K. Spiekermann group, CCG-
Leukemia, GSF National Research Center for 
Environment and Health, Munich, Germany. Sub 
cloned from pCDNA6-FLT3-WT, provided by 
Dr. D. G. Gilliland (Harvard Medical School, 
Boston, MA, USA). 
  
   
FLT3-ITD constructs 
MIY-FLT3-NPOS    Prepared in K. Spiekermann group, CCG- 
MIY-FLT3-W51  Leukemia, GSF National Research Center for 
Environment and Health, Munich, Germany. Sub 
cloned from pCDNA6-FLT3-W51/NPOS, 
provided by Dr. D. G. Gilliland (Harvard Medical 
School, Boston, MA, USA). 
 
 
Figure 3.1.2: Amino acid sequence of the FLT3-ITD constructs. FLT3-W51 has a duplication of 7 AA 
(REYEYDL), between AA 601/602, whereas, FLT3-NPOS has duplication of 28 AA 
(CSSDNEYFYVDFREYEYDLKWEFPRENL), inserted between AA 611/612 in the human FLT3-WT. 
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FLT3-WT- mutant constructs 
FLT3-WT-ins595R 
FLT3-WT-ins596RE     
FLT3-WT-ins597EY      Constructs made for this study 
FLT3-WT-ins597REY 
FLT3-WT-ΔR595 
 
FLT3-ITD- mutant constructs 
FLT3-W51-R602A 
FLT3-W51-R602E 
FLT3-W51-R602K 
FLT3-W51-ΔR602      Constructs made for this study 
FLT3-W51-ΔR595 
FLT3-W51-∆E603 
FLT3-W51-∆Y604 
FLT3-NPOS-ΔR623 
FLT3-W51-Y589F 
FLT3-W51-Y591F 
FLT3-W51-Y597F 
FLT3-W51-YY589/591FF 
FLT3-W51-YY589/597FF 
FLT3-W51-YY589/599FF 
FLT3-W51-YY591/597FF 
FLT3-W51-YY597/599FF 
3.1.3 Primer oligonucleotides 
All the primer oligonucleotides were synthesized from Metabion International, Martinsreid, 
Germany. 
Primers for FLT3 sequencing 
The primers for sequencing was designed using the FLT3 sequence (gene bank accession 
number-NM_004119) taken from NCBI. 
pMSCV   
5’- cccttgaacctcctcgttcg-3’  1-260 bp of FLT3 
FLT3-2                     
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 5’-aagacctcgggtgtgcgttg-3’  260-600 bp 
FLT3-3                    
5’-acgccctggtctgcatatc-3’  600-940 bp 
FLT3-4   
5’- cgggctcacctgggaattag-3’  940-1280 bp 
FLT3-5   
5’-tttgcaatcataagcaccagc- 3’  1280-1620 bp 
FLT3-6                      
5’-atacaattcccttggcacatc-3’  1620-1960 bp 
FLT3-7   
5’-aacggagtctcaatccagg-3’  1960-2300 bp 
FLT3-8   
5’-cagcatgcctggttcaagag-3’  2300-2640 bp 
FLT3-9    
5’-aggcatctacaccattaagag-3’  2640-2980 bp 
 
Primers for mutagnesis of FLT3-WT and FLT3-ITDs 
FLT3-WT-ins595R sense   
5'-gagtacttctacgttgatttcagaagagaatatgaatatgatctcaaatgg-3' 
FLT3-WT-ins595R antisense   
5'-ccatttgagatcatattcatattctcttctgaaatcaacgtagaagtactc-3' 
 
FLT3-WT-ins597EY sense 
5'-ctacgttgatttcagagaatatgagtacgaatatgatctcaaatggg-3' 
FLT3-WT-ins597EY antisense   
5'-cccatttgagatcatattcgtactcatattctctgaaatcaacgtag-3' 
 
FLT3-WT-ins597REY sense  
5'-ctacgttgatttcagacgggaatatgagtacgaatatgatctcaaatg gg-3' 
FLT3-WT-ins597REY antisense-   
5'-ccc atttgagatcatattcgtactcatattcccgtctgaaatcaacgt ag-3' 
 
FLT3-W51- R602E sense 
5'-gatttcagagaatatgaatatgatctcgaagaatatgaatatgatctcaaatgggag-3' 
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FLT3-W51- R602E antisense 
5'-ctcccatttgagatcatattcatattcttcgagatcatattcatattctctgaaatc-3' 
 
FLT3-W51- R602K sense  
5'-gatttcagagaatatgaatatgatctcaaagaatatgaatatgatctcaaatgggag-3' 
FLT3-W51- R602K antisense  
5'-ctcccatttgagatcatattcatattctttgagatcatattcatattctctgaaatc-3' 
 
FLT3-W51- ΔR602 sense 
5'-gatttcagagaatatgaatatgatctcgaatatgaatatgatctcaaatgggag-3' 
FLT3-W51- ΔR602 antisense 
5'-ctcccatttgagatcatattcatattcgagatcatattcatattctctgaaatc-3' 
 
FLT3-W51- ΔR595 sense 
5'-ttctacgttgatttcgaatatgaatatgatctcaga-3' 
FLT3-W51- ΔR595 antisense 
5'-tctgagatcatattcatattcgaaatcaacgtagaa-3' 
 
FLT3-W51- ΔE603 sense 
5'-gatttcagagaatatgaatatgatctcagatatgaatatgatctcaaatgggag-3' 
FLT3-W51- ΔE603 antisense 
5'-ctcccatttgagatcatattcatatctgagatcatattcatattctctgaaatc-3' 
 
FLT3-W51- ΔY604 sense  
5'- gatttcagagaatatgaatatgatctcagagaagaatatgatctcaaactcaaatgggag-3' 
FLT3-W51- ΔY604 antisense 
5'- ctcccatttgagatcatattcttctctgagatcatattcatattctctgaaatc-3' 
 
FLT3-NPOS- ΔR623 sense 
5'-gagtacttctacgttgatttcgaatatgaatatgatctcaaatggg-3' 
FLT3-NPOS- ΔR623 antisense 
5'-cccatttgagatcatattcatattcgaaatcaacgtagaagtactc-3' 
 
FLT3-Y589F sense  
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5'-ggctcctcagataatgagttcttctacgttgatttcagagaa-3' 
FLT3-Y589F antisense 
5'-ttctctgaaatcaacgtagaagaactcattatctgaggagcc-3' 
 
FLT3-Y591F sense  
5'-ggctcctcagataatgagtacttcttcgttgatttcagagaatat-3' 
FLT3-Y591F antisense 
5'-atattctctgaaatcaacgaagaagtactcattatctgaggagcc-3' 
 
W51-Y589/Y591F sense 
5'-gataatgagttcttctacgttgatttcagagaatatgaatttgatctcaga-3' 
W51-Y589/Y591F antisense 
5'-tctgagatcaaattcatattctctgaaatcaacgtagaagaactcattatc-3' 
 
FLT3-WT-Y589/Y597FF sense 
5'-gctcctcagataatgagttcttctttgatttcagagaatatgaatatg-3' 
FLT3-WT-Y589/Y597FF antisense 
5'-catattcatattctctgaaatcaacaaagaagaactcattatctgaggagc-3' 
 
3.1.4 Cell lines 
Human 
HEK-293      Hunam embryonic kidney cells (Graham, 1977) 
Murine 
Ba/F3      IL-3-dependent pro-B cell line 
WEHI-3B  myelomonocytic Leukemia-cell line (Warner, 
1969); established from macrophage cells of 
BALB/c-Mice; cells produce the haematopoietic 
growth factor IL-3 
 
3.1.5 Chemicals, enzymes, inhibitors and cytokines 
Chemicals 
Acrylamide/Bisacrylamide 30%     Roth, Karlsruhe 
Agarose        Sigma, Taufkirchen 
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Ammonium peroxidesulfate (APS)    BioRad, Munich 
Aprotinin        Sigma, Taufkirchen 
Bio-Rad Protein Assay Dye Reagent   BioRad, Munich 
Bovineserum albumin (BSA)     Fluka, Buch, Switzerland 
Bromphenolbue       Sigma, Taufkirchen 
Dimethylsulfoxide       Sigma, Taufkirchen 
1,4-Dithiothretiol       Merck, Darmstadt 
DNA Ladder       Promega, Mannheim 
dNTPs        Roche, Mannheim 
ECL Detection Reagent      Amersham Pharmacia, Freiburg 
EGTA(ethylen glycol-bis(2-aminoethylether)- 
N,N,N',N'-tetraacetic acid)      Sigma, Taufkirchen 
Acetic acid       Merck, Darmstadt 
Ethanol        Merck, Darmstadt 
Fetal calf serum (FCS)      Sigma, Taufkirchen 
Glycerin        Sigma, Taufkirchen 
HEPES (N-(2-Hydroxyethyl) piperazine-N´-   Sigma, Taufkirchen 
(2-ethanesulfonic acid))       
High Performance Chemiluminescence Film  Amersham Pharmacia, Freiburg 
Leupeptin A        Sigma, Taufkirchen 
2-Mercaptoethanol       Sigma, Taufkirchen 
Methanol        Merck, Darmstadt 
Sodium acetate       Sigma, Taufkirchen 
Sodium fluoride      Sigma, Taufkirchen 
Sodium vanadate       Sigma, Taufkirchen 
Nitrocellulose membrane     Schleicher&Schüll, Dassel 
Pepstatin A        Sigma, Taufkirchen 
Phenylmethylsulfonylfluoride (PMSF)    Sigma, Taufkirchen 
Phosphatase Inhibitor Cocktail 2     Sigma, Taufkirchen 
Ponceau        Sigma, Taufkirchen 
Polyfect Transfection Reagent     Qiagen, Hilden 
Polybrene        Sigma, Taufkirchen 
Proteinase Inhibitor Cocktail-(P8340)    Sigma, Taufkirchen 
Protein G-Agarose       Roche, Mannheim 
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Protein A-Agarose       Roche, Mannheim 
Propidium iodide      Sigma, Taufkirchen 
Rainbow Marker       Amersham, Freiburg 
Sodiumdodecylsulfate (SDS)     BioRad, Munich 
Tetramethylethylendiamin (TEMED)    Serva, Heidelberg 
Tris(hydroxymethyl)aminomethan (Tris)    Merck, Darmstadt 
Triton-X-100        Sigma, Taufkirchen 
Trypan Blue        Invitrogen, Karlsruhe 
Tween 20        Merck, Darmstadt 
 
Enzyme 
Taq DNA Polymerase      Roche, Mannheim 
Pfu Turbo DNA Polymerase      Stratagene, Heidelberg 
T4-DNA-Ligase       Roche, Mannheim 
T4-DNA-Ligase       Fermentas, St.Leon-Rot 
Restriction enzymes (NEB, Frankfurt) 
 
Inhibitor 
PKC412 (CGP 41251)      Novartis, Basel, Switzerland 
 
Cytokine 
FLT3-Ligand (FL), recombinant human    Promocell, Heidelberg 
Interleukin-3 (IL-3), recombinant murine    Biosource, Camarillo, USA 
 
The lyophilised cytokines were reconstituted in 0.1% BSA solution, aliquoted and stored at – 
-20°C. 
 
3.1.6 Kits 
BigDye Terminator Cycle Sequencing Kit  Appl. Biosystems, ForsterCity, 
USA 
PCR Purification Kit       Qiagen, Hilden 
Qiagen Endofree Plasmid Maxi Kit     Qiagen, Hilden 
QIAprep-spin Miniprep Kit      Qiagen, Hilden 
QuikChange Site-Directed Mutagenesis Kit   Stratagene, Heidelberg 
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3.1.7 Laboratory equipment 
Blotting chamber       Bio-rad, Munich 
Cell culture CO2 incubator      Haereus, Rodenbach 
Cell culture hood       Bio Flow Technik, Meckenhein            
Centrifuges ROTIXA/P      Hettich, Tuttlingen 
Developing machine M35X-OMAT Processor   Kodak AG, Stuttgart 
Eppendorf ultracentrifuge 2K15  Sigma-Aldrich Chemie GmbH, 
Taufkirchen 
FACS scan  Beckton Dickinson, Mountain 
View, CA, USA 
Fridge (4°C, -20°C)       Siemens AG      
Fridge (-80°C)  UF80-450S  Colora Messtechnik GmBH, Lorch                   
Gel electrophoresis systems      Bio-rad, Munich 
Heating block BT 130-2  HLC, Haep Labor Consult, 
Bovenenden 
Liquid nitrogen tank   Cryoson, Schöllkrippen 
Microscope        Carl Zeiss Jena 
pH-meter 766   VWR International, Ismaning 
Rotor Ti 75        Beckman, Palo Alto, CA 
Shaker        Edmund Bühler, Tübingen 
Sequencer (ABI Prism 310 Genetic Analyzer)  Appl. Biosys, ForsterCity, USA 
Spectophotometer Smartspec TM 3000    Bio-rad, Munich 
Ultracentrifuge L7-65      Beckman, Palo Alto 
Vortex        Cenco, Breda, The Netherlands 
Water bath        HAAKE, Karlsruhe 
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3.1.8 Software 
Adobe Illustrator  Adobe Systems, 
Unterschleißheim 
Adobe Photoshop  Adobe Systems, 
Unterschleißheim 
BioEdit 7.0  ISIS Pharmaceutica, Carlsbad, 
USA 
Cellquest 3.3        Beckton Dickinson, Heidelberg 
EndNote 6.0.2       Thompson ISI, Carlsbad, CA, USA 
Microsoft Office 2003      Microsoft, Redmond, WA, USA 
SigmaPlot 6.0       SPSS Incorporated, Chicago, USA 
TINA 2.0        Raytest, Straubenhardt 
WinMDI 2.8        Joseph Trotter 
 
 
3.2 Methods 
3.2.1 Bacterial cultures 
3.2.1.1 Preparation of competent E.coli cells 
For the preparation of competent cells using CaCl2 method, E.coli (XL-10) was cultured 
overnight in 50 ml LB medium without antibiotics. Next morning the cells were split 1:10 in 
LB medium and grown until the OD600 = 0.4-0.9. The cells were cooled on ice for 15 min and 
then centrifuged at 3000 rpm for 5 min. The supernatant was discarded, the cells resuspended 
in 50 ml of ice cold TbI buffer and again incubated on ice for 15 min. After centrifugation the 
cells were resuspended in 2-4 ml of ice-cold TbII buffer. 100 µl aliquots of cells were 
transferred in Eppendorf- tubes and frozen down immediately in dry ice for 1 hour. The 
aliquots were stored at -80°C. 
 
Tfb I:    30 mM KOAc, 100 mM KCl, 50 mM MnCl2, 10 mM CaCl2, 
15 % (v/v) Glycerin (Sterilfiltration, store at 4°C) 
Tfb II:    5 ml 1 M NaMOPS (pH 7,0), 75 mM CaCl2, 10 mM KCl, 
15 % (v/v) Glycerin (Sterilfiltration, store at 4°C) 
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3.2.1.2 Transformation of competent E.coli  
The competent cells were thawed on ice and 25 µl of the cells were transferred in a tube. 1-10 
µl DNA,10 µl 5xKCM (500 mM KCl, 150 mM CaCl2, 250 mM MgCl2) and remaining water 
were added to make up the final volume to 50 µl. The mix was incubated on ice for 20 min 
and then for 10 min at room temperature. After the incubations 250 µl of LB medium was 
added, the tubes were incubated at 37°C for one hour to let cells recover from the shock. After 
1 hr incubation 150 µl of the cells were spread on LB agar plate with containing appropriate 
antibiotics and incubated at 37° overnight. 
 
3.2.1.3 Preparation of plasmid DNA 
Mini-Prep 
Pasmid Mini-Kit (Qiagen, Hilden) 
MaxiPrep 
Plasmid Maxi-Kit (Qiagen, Hilden) 
 
3.2.2 Molecular biology techniques 
3.2.2.1 Digestion of DNA with restriction enzymes 
All the mini and maxi-Plasmid preparations were checked for the correct DNA identity using 
enzymatic restriction enzyme digestion. Restriction enzymes from New England Biolabs 
(Frankfurt, Germany) were used and the conditions were selected corresponding to the 
statements of the manufacturer. All the digested products were checked in 1% agarose gels 
containing ethidium bromide to detect the DNA. 
 
3.2.2.2 Mutagenesis 
  To introduce point mutants, deletions, insertions or substitutions, site directed mutagenesis 
was done using the ´QuikChange site Directed Mutagenesis Kit (Stratagene, La Jolla, USA). 
For mutagenesis, the primers were designed with a length between 40 and 60 bases, with a 
melting temperature of ≥75°C and containing the desired mutation in the middle. Optimum 
primers had a minimum GC content of 40% and terminated on one or more C and G bases at 
the 3’-end.  Each reaction contained 35 µl H2O, 5 µl 10xPCR buffer, 3 µl Quick Solution, 
primers. Then template DNA, 1µl dNTPs (10mM) and water were added up to a final volume 
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of 50 µl.  PCR conditions and further steps were followed as directed by the manufacturer. 
Sequencing of the constructs was performed to confirm the correct positioning of the 
mutations and no unwanted additional mutations. 
  
3.2.2.3 Agarose Gel Electrophoresis 
To determine the size of DNA fragments, to estimate DNA quantity and to separate and 
isolate the DNA fragments Agarose gel electrophoresis was used. Concentration of the 
agarose gels (0.8-2%) was adjusted according to the size of the DNA fragments, with smaller 
fragments needing higher concentration of agarose. The correct amount of powdered agarose 
(Gibco BRL, Germany) was added to a measured quantity of electrophoresis buffer (1xTBE), 
then the mix was heated slurry in a microwave oven until the agarose was dissolved. After 
cooling of this solution to 50°C, ethidium bromide solution [0,5 μg/ml] (Roth, Germany) was 
added and the warm solution was poured into a chamber. After polymerization (ca. 30-40 min 
at room temperature), the gel was placed in an electrophoeresis chamber with 1xTBE buffer. 
The samples were mixed with 6x loading buffer (Promega) and loaded into the slots of the 
submerged gel.  Then the DNA fragments were visualised under a UV light. To determine the 
size of the DNA fragments, a marker with defined fragment sizes was applied.  
 
TBE-buffer (5x):  54,0 g Tris, 27,5 g boric acid , 20 ml 0,5 M EDTA,and make up to 1000 ml 
 
   
3.2.2.4 Sequencing 
For sequencing of the plasmids, Big Dye terminator sequencing kit was used. For 1 PCR 
reaction, 2 µl of Big dye, 1 µl water, 1 µl primer (10pmol) and 1 µl DNA (75ng-200ng) were 
used. Following PCR conditions were used: 30 cycles at 94°C 10 sec, 50°C 5 sec, 60°C 4 
min; 4°C. The PCR products were purified in a two step manner. In the first step 25µl of 1:24, 
3M NaAc:ethanol was added and centrifuged at 4000 rpm for 20 min. Supernatant was 
discarded and 100 µl of 70% ethanol was added and centrifuged at 4000 rpm for 10 min. Then 
the supernatant was discarded and the pellet was kept till dry. DNA was dissolved in 10 µl of 
water and transferred into sequencing tubes and subsequently analysed in Prism 310 Genetic 
Analyzer.   
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3.2.3 Cell culture 
3.2.3.1 Cell culture conditions 
All cell lines used in this study were cultivated in an incubator set at 37°C with 95% relative 
air humidity in the presence of 5% CO2 (for buffering). All cell culture mediums, RPMI-1640 
and Dulbecco’s modified Eagle Medium (DMEM), were supplemented with 10% FCS and 
5U/ml of pencillin and streptomycin each respectively.  
 
3.2.3.2 Culture of adherent cell lines 
The human embryonic kidney cell line 293 was maintained in DMEM medium. These cells 
grow as monolayers which are held together to the substratum by mucoproteins and 
sometimes by collagens. For the subculturing of the cells, the confluent cells were washed 
once with DPBS and then treated with trypsin supplemented with 0,5M EDTA for 5 mins to 
release the cells from monolayers. Each 2 to 3 days the cells were split in 1:5 ratios into new 
flasks.  
 
The murine myelomonocytic leukemic cell line WEHI-3B was grown in RPMI-1640 medium. 
These cells are trypsin sensitive and were therefore incubated with DPBS (without Ca2+ or 
Mg2+) for 15 min and cells scrapped using cell scrapers. The cells were then split at a ratio of 
1:5 into a fresh culture flask. The supernatant was used as a source of murine IL-3 supplement 
to cultivate the IL-3 dependent Ba/F3 cells.  It was filtered and stored at -20°C until use.  
 
3.2.3.3 Culture of suspension cell lines 
The IL-3 dependent murine proB cell line Ba/F3 cells was grown in RPMI-1640 medium 
supplemented with 10% WEHI conditioning medium as a source of murine IL-3. The cells 
were split every two or three days at 1:20 ratio. 
3.2.3.4 Freezing and thawing of cells 
Cell stocks can maintain for years by storing them in liquid nitrogen. To freeze the cells, 1 x 
107 cells were pelleted, resuspendended in 1 ml of freezing medium and transferred to a 1.5 
ml cryo ampoules (Nunc, Roskilde, Denmark). In order to minimize the cellular injury 
induced by freezing and thawing procedures (intracellular ice crystals and osmotic effects), 
10% of cryoprotective agent: dimethyl sulphoxide (DMSO) is added to the freezing medium. 
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The ampoules are cooled up before and every step is performed on ice. While short-term 
preservation of cell lines using mechanical freezers (-80°C) is possible, storage in liquid 
nitrogen (-196°C) or its vapor (-120°C) is much preferred.  
For optimal recovery rapid thawing of the cells is essential. Therefore the cells were thawed 
in 37°C water bath and, as DMSO in the freezing medium are toxic to the cells, subsequently 
diluted with DPBS or culture medium at a ratio of 1:20 and centrifuged at 1000 rpm for 5 
min. The supernatant was discarded and the pellet resuspended in culture medium. All the 
thawed cell lines were cultured for 3 days before being used for experiments. 
 
Freezing medium:    90 % FCS, 10 % DMSO 
 
3.2.3.5 Transfection of the 293 cells 
The 293 cell line can be transfected with high efficiency. Hence this cell line is used for 
protein overexpression and transient transfections for producing high titre retroviral 
supernatant. For transient transfection, cells were seeded at a density 5x105/ml. The next day 
the cells were transfected with 2µg plasmid (cloned in MSCV-IRES-YFP) mixed with 2µg of 
EcoPack (Retroviral packaging genes) and transfected with Polyfect transfection Reagent 
(Stratagene, Hiedelberg) according to the manufacturers instructions. 48 hours after 
transfection cells were either lysed to analyse protein expression or the supernatant was 
collected and filtered through a 0.45 m filter to stably tranduce BaF3 cells.  
 
3.2.3.6 Stable transduction of Ba/F3 cells 
2x105/ml Ba/F3 cells were seeded in 200µl of growth medium RPMI-1640 and subsequently 
transduced once with 200µl of retroviral supernatant collected from the transient transfection 
of 293 cells in the presence of polybrene (8µg/ml). After 4-12 hours 1 ml of medium was 
added to avoid the toxic action of the polybrene on the cells. The cells were expanded and 
sorted after 5 days. 
 
3.2.3.7 Cell sorting by facs 
Five days after the transduction of the Ba/F3 cells, positive cells expressing YFP/GFP were 
sorted using the Vintage SE Flowcytometer equipped with a turbo-sort DEVICE (assortment 
of 20.000 cells/s), and the Cellquest 3,3 software. For the cell sorting, cells were centrifuged 
1000 rpm for 5 mins and resuspended in 1ml of FACs buffer (RPMI-1640 with 1µg/ul of 
Materials and Methods 
 27
Propidium Iodide). The sorted YFP/GFP positive cells were expanded and examined after 3 
days in the FACS Calibur Flowcytometer (Beckton Dickinson, Heidelberg) for the purity of 
the population. Cell populations with > 95 % YFP/GFP positive cells are taken for further 
experiments or they are resorted to attain > 95 % purity 
 
3.2.3.8 Proliferation assays 
Determination of viable cell number is important aspect of cell culture especially for seeding 
the cells and proliferation experiments. In proliferation experiments, viable cells are counted 
at the background of various factors such as in the presence or absence of cytokines or 
inhibitors. 
 
For the proliferation experiments with Ba/F3 cell lines, cells were seeded at a density of 4 x 
104 cells/ml  in the presence of IL-3, or inhibitors as indicated. Viable cells were counted at 
24, 48 and 72 hours in a standard hemacytometer after staining with trypan blue. The IC50 was 
defined as the concentration of inhibitor at which 50% of cells were viable compared to cells 
grown in the absence of inhibitor. 
 
3.2.3.9 Trypan blue exclusion method 
Trypan blue does not enter viable cells but dead cells, so that they appear blue and can be 
distinguished from viable cells under the microscope. For determination of the viable cells, 
cells were mixed with a ratio of 9:1 (cells:typan blue) and counted under an optical 
microscope using a standard neubauer chamber.The formula for the calculation of viable cells 
is: cells /ml = number of viable cells /4 x dilution factor x 10,000.    
 
3.2.3.10 Cell starving for cell lysis 
To analyse the phosphorylation of specific signalling pathways it is necessary to starve the 
cells before cell lysis, to reduce the background of phosphorylated proteins.  The cells were 
washed twice with PBS and cultivated subsequently in starving medium.  The maximum time 
the cells could be starved without effecting the morphology of cells was  determined. For 
Ba/F3 cells a maximum starvation time of 24 hr was applied. 
Starving medium:   RPMI-1640 or DMEM + 0.3 % FCS + 50 U/ml Penicillin + 50 U/ml 
        Streptomycin 
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3.2.3.11 Stimulation of cells with cytokine/ligand before cell lysis 
Cells were treated frequently with cytokine/ligand before cell lysis. Cell lines expressing 
RTKs are stimulated upon binding of respective ligands/cytokines and show upregulation of 
signalling pathways. The cytokine/ligand stimulated cells serve as positive controls for 
signalling pathways when the wild type RTKs is compared with mutant RTKs. For 
stimulation of cells with cytokines/ligand, cells were incubated with a defined quantity of 
cytokine/ligand in 1 ml of starving medium for 5 mins. Then the cells were centrifuged at 
1000 rpm at 4°C to stop the reaction. The cell pellet was lysed in lysis buffer.  
 
3.2.4 Protein Biochemistry 
3.2.4.1 Cell lysis 
For cell lysis the starved/cytokine/ligand induced cells were centrifuged at 1000rpm for 5 min 
at 4oC. Then the supernatant was discarded and 1ml of lysis buffer (for 3 X 106 cells) was 
added and cells were transferred to 1.5ml Eppendorf tubes. Then the tubes were rotated at 10 
rpm at 4°C on a rotator for 30 min, then the tubes were centrifuged at 14,000 rpm for 20 min. 
Supernatants from the tubes were transferred into fresh eppendorf tubes and stored at -20°C 
until further use. 
 
Lysis Buffer:    50 mM Hepes pH 7,5, 150 mM NaCl, 1 mM EGTA, 10 % glycerol, 
1 % Triton X-100, 100 mM NaF, 10 mM Na4P2O7 
Add fresh for 10 ml: 50 μl Aprotinin (200x), 100 μl 0,1 M 
PMSF, 100 μl 0,1 M orthovanadate 
 
3.2.4.1 Protein Quantification 
The determination of the protein concentration in cell lysates was done by the Bradford 
method (Bradford, 1976). The Bradford dye contains Coomassie Brilliant Blue G-250, whose 
absorption maximum increases upon binding to basic and aromatic groups of proteins from 
495 to 595 nm.  The intensity of the dye correlates directly with the concentration of protein 
in the lysate and can be measured in a spectral photometer.  The dye has to be diluted at 1:5 
with water before use.   5μl of the lysate and 995μl of the BioRad-Dyes were mixed and 
incubated for 10 min in RT.  Subsequently the absorption was measured in 595 nm in the 
spectral photometer against 1ml of 1:5 diluted Bio-Rad dye.  To determine the absolute 
concentration of the samples, standards made from different concentrations of BSA (1, 5, 10, 
15, 20 and 25ug) was measured in parallel and concentrations of the samples calculated. 
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3.2.5 3.2.4.2 SDS-Polyacrylamidegelelectrophoresis  
SDS-PAGE was performed as described by Laemmli (Laemmli, 1970). In SDS-PAGE 
proteins were separated according to their molecular weight. A gradient gel (range 7.5- 12.5% 
polyacrylamide) was used for standard applications. For SDS page protein samples (whole 
cell lysates) were first denaturized by boiling at 95°C for 5 minutes in SDS laemmli buffer; 40 
to 100 µg protein was loaded into the gel and run at 150 volts in running buffer to separate 
electrophoretically for 8-12 hours time. A marker (Rainbow marker) with well-characterized 
proteins allows identifying the molecular weight of unknown proteins.  
 
Laemmli-Buffer (2x):   187.5 mM TRIS, 6 % SDS, 30 % Glycerol 
7,5 % separting gel:   5.65 ml 1.5 M Tris-Buffer (pH 8,8), 6,25 ml Polyacrylamide 
(30 %), 150 μl 10 % SDS, 50 μl 10 % APS, 2.9 ml H2O, 1.5 μl 
TEMED 
12,5 % separating gel:   5.65 ml 1.5 M Tris-Buffer (pH 8,8), 3,75 ml Polyacrylamide 
(30 %), 2 g Sucrose, 150 μl 10 % SDS, 50 μl 10 % APS, 5.4 ml H2O, 
1.5 μl TEMED 
4 % stacking gel:   2.5 ml 1.5 M Tris-Buffer (pH 6.8), 1.3 ml Polyacrylamide (30 %), 
100 μl 10 % SDS, 50 μl 10 % APS, 6.1 ml H2O, 10 μl TEMED 
Elektrophoreses buffer (10x):  151.4 g Tris, 720,65 g glycin, 50 g SDS, ad 5000 ml, pH 8.3 with HCl 
 
 
3.2.6 3.2.4.3 Western Blot analysis 
After electrophoresis, proteins are transferred onto a nitrocellulose membrane in a blotting 
chamber using a semidry method (Towbin, 1979, Kyhse-differently, 1984). Blotting was 
performed for 3 h at 250mA.  To confirm the protein transfer, the membrane was stained 
shortly with Ponceau dye, a transient red staining which binds every protein. Afterwards the 
proteins on the membrane were blocked by incubating with 0.25% gelatin in NET buffer 
(1xG-NET) for 1 h (3x 20min) and then incubated overnight with appropriate antibody 
dilutions. For analysis, the membrane was washed 3 times for 15 minutes in TBST and then 
incubated for 1 hour at room temperature in secondary antibody, a species-specific 
horseradish peroxidase (HRP) conjugated antibody diluted in the G-Net solution. To wash 
away unspecifically bound antibody the membrane was washed 3 times for 15 minutes in 
TBST. Protein/antibody complexes were detected using chemiluminisense (ECL-Enhanced 
Luminol Reagent, Amersham) system. This western blot chemiluminescence reagent is a non-
radioactive light emitting system, which detects proteins immobilized on a membrane, from 
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the oxidation of luminol, which results in light emission at a wave length of 428 nm, captured 
by a autoradiograph film 
 
Transblot without Methanol(10x):   72.75 g Tris, 36,63 g Glycine, 0.475 g SDS, ad 5000 ml 
Transblot-Buffer:  80 ml Transblot without Methanol, 200 ml Methanol, make upto 
1000 ml 
Ponceau:     0.5 g Ponceau S, make upto 100 ml 
Net (10x):  438.3 g NaCl, 93.6 g Na2EDTA, 302.85 g Tris, 25 g Triton-X-100, 
ad 5000ml, pH 7,7 with HCl 
G-Net:  2.5 g Gelatin, 100 ml Net (10x), make upto 1000 ml 
TBS (10x):     12.11 g Tris, 87.66 g NaCl, ad 1000 ml (pH 8,8) 
TBST:      100 ml TBS (10x), 1 ml Tween 20, make upto 1000 ml 
. 
 
3.2.4.4 Stripping of Nitrocellulose-Membrane 
The nitrocellulose membrane with proteins can be used for detection of multiple proteins, but 
the membrane should be devoid of previous antibody. Hence, the nitrocellulose membrane 
was stripped with stripping solution (warmed till 56oC). the membrane was kept in stripping 
solution for 40 min at 56oC, washed 3X 20min with TBST, blocked in GNET and used for 
subsequent analysis as described above..   
 
Stripping-solution:   62.5 mM Tris pH 6.8, 0.1 M β-Mercaptoethanol, 2 % SDS 
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4 RESULTS 
4.1 Arginine 595 is duplicated in patients with acute leukemias carrying internal 
tandem duplications of FLT3 and is critical for its transforming potential 
4.1.1 Clinical and laboratory data of the patients taken for this study. 
Two hundred and eighty four patients diagnosed with acute leukemias and carrying FLT3-
ITD were taken for this study from the patient data bank of the Laboratory for Leukemia 
Diagnostics, University Clinic of Grosshadern, Munich. All patients gave informed consent 
before entering the study. The study design adhered to the principles of the Declaration of 
Helsinki and was approved by the ethics committees of the participating institutions. Clinical 
and laboratory data of patients analyzed in this study are given in Table 4.1. Ten patients 
included in this study had no clinical data.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1.1: Clinical and laboratory data of the patients analyzed in this study  
 
Number of patients = 284 
Age 
Range 
Median 
18-89 
60.5 
Gender 
Female 
Male 
163 
121 
FAB class 
AUL 
Biphenotypic 
ALL 
AML M0 
AML M1 
AML M2 
AML M3 
AML M4 
AML M5 
AML M6 
MDS 
AML with unknown FAB 
2 
3 
4 
6 
63 
49 
28 
39 
21 
4 
3 
52 
Patients without clinical data ------ 10 
WBC count 
Median 
Range 
50000 
12000-67500 
Cytogenetic abnormality 
Favourable 
Intermediate 
Adverse 
Unknown 
29 
185 
11 
49 
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4.1.2 FLT3-ITDs are a higly heterogenous group of mutations 
Sequencing of cDNA of 284 patients carrying FLT3-ITDs was done using patients specific 
primers at the Laboratory of leukaemia diagnostics, Grosshadern, munich. DNA from these 
patients used for sequencing was previously checked for the FLT3-ITDs using a PCR method 
and then doing an agarose gel electrophoeresis.  Then sequence of the JM region of ITDS 
was the translated into amino acids. Amino acid analysis revealed that 111 patients carried 
pure tandem duplication whereas 163 patients had additional amino acid insertions at the 
start of duplication.  The length of of duplication varied from 2AA to 42 AA with a median 
length of 17 AA (Table 4.1.2). 
 
 
 
 
 
 
 
 
Table 4. 1.2: Characteristics of the duplications found in this study. 
 
 
4.1.3 Internal tandem duplications are located in the common motif YVDFREYEY 
and include R595 in 77% of patients  
Analysis of the frequency of single AA in the duplicated region revealed that arginine 595 
was the most frequently duplicated single AA in 77%, followed by Y597 in 74%, F594 and 
E596 in 73% of all patients, respectively (Figure 4.1.3.1). In 95% of the patients at least one 
AA within the stretch Y591 to Y599 (YVDFREYEY) was duplicated. Next, we analyzed the 
frequency of AA combinations statistically, ranging in length from 1 to 30 AA within the 
duplicated region. As shown in Figure 4.1.3.2A the single R595 is subsequently followed by 
the combination of amino acids EY (AA596-597) and REY (AA595-597) in 70% of all 
patients.  
 
These findings point to a commonly duplicated motif that centers around R595 within the Y-
rich stretch from AA 591 to 599 (YVDFREYEY). We hypothesized that this region might 
play an important role for the transforming activity of FLT3-ITDs. To confirm this 
Number of patients = 284 
Pure tandem duplications 
Tandem duplications  + 
additional insertions 
118 
166 
Length of AA duplications 2-42 AA 
Median of AA duplications 17 AA 
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hypothesis, we analyzed the patients that carried the shortest ITD. Figure 4.1.3.2B shows the 
duplicated sequences of 25 patients ranging in length from 2 to 8 AA. The patient with the 
shortest duplication (2 AA) showed insertion of R595 and E596. All but 4 patients 
(21/25=84%) had duplications of R595. Moreover, all patients had duplications of at least 
one amino acid of the protein stretch REYEY (AA 595 to 599). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1.3.1: Analysis of the AA composition in the duplicated region in FLT3-ITDs: Frequency of single 
AAs by position in the duplicated region is shown. For each position the most frequent single AA was selected. 
 
 
Figure 4.1.3.2: Duplications locate in the motif YVDFREYEY and include R595 in 77% of patients: (A) 
Most frequent AA combinations within the duplicated region, sorted by length from 1 to 30 AA. (B) Panel 
showing the duplicated sequences of 25 patients ranging from 2 to 8 AA.  
 
Results 
 34 
 
4.1.4 Insertion of a single arginine between AA 595 and 596 in FLT3-WT confers IL-3 
independent growth to Ba/F3 cells 
 
4.1.4.1 Generation of R595 insertion mutants 
The acquisition of FLT3-ITD mutations in the FLT3 gene was shown to induce constitutive 
activation of the receptor and ligand-independent cell growth in different cell 
lines(Hayakawa et al., 2000; Kindler T, 2005; Kiyoi et al., 1998; Yamamoto et al., 2001). To 
validate our hypothesis that duplication of R595, which is found in 77% of patients with 
FLT-ITDs plays an important role for the transforming activity of the receptor, we introduced 
an arginine in the FLT3-WT cDNA between positions 595 and 596 (FLT3-ins595R).  The 
second and third most frequent duplicated AA combinations E596/Y597 (FLT3-ins597EY) 
and R595/E596/Y597 (FLT3-ins597REY), and also the shortest duplication found in 
patients, i.e. AA combination R595/E596 (FLT3-ins597RE) were also generated by in vitro 
mutagenesis (Figure 4.1.4.1). The correct sequences of all mutants were confirmed by 
nucleotide sequencing. 
 
 
Figure 4.1.4.1: Map of insertion mutants generated in FLT3-WT: Localization of four insertion mutants of 
FLT3 generated by duplication of 1 to 3 AA of the stretch between AA 595 to 597 
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4.1.4.2 Generation of R595 insertion mutant cell lines 
Activating mutations of FLT3 confer factor independent growth to IL-3 dependent Ba/F3 
cells in vitro. Hence we transduced the Ba/F3 cells with the constructs   FLT3-WT-ins595R, 
FLT3-WT-ins597EY, FLT3-WT-ins596RE, FLT3-WT-ins597REY. FLT3-WT, mock-
expressing cells (MIY) as negative controls and FLT3-ITD-W51 as positive control were also 
transduced in the Ba/F3 cells. Transduced EYFP-positive cells were sorted by FACS on the 
basis of EYFP fluorescence and were expanded in the presence of IL-3. After expansion the 
positive cells were checked for YFP expression in the FACS calibur. 95% or above cells 
must be YFP positive for further studies or they are resorted. Then the cells are checked for 
FLT3 expression using PE- conjugated CD135, a FLT3 specific surface antibody in FACS 
caluber. Only the cells expressing the FLT3 show a shift in flouresence intensity (Figure 
4.1.4.2). 
 
 
 
Figure 4.1.4.2: Overexpression of the FLT3 receptor. Example histograms for four of the many FLT3-WT and 
FLT3-ITD cell lines generated for this study are shown, whereby the cell number is represented against the 
fluorescence intensity in channel FL2. The black histogram represents the cells after colouring with IgG1-PE-
antibody (control), the white histogram the cells after colouring with specific CD135-antibody. 
 
 
Results 
 36 
 
4.1.4.3 Transforming potential of cells expressing a single R595 duplication 
Ba/F3 cells stably transduced with FLT3-WT, FLT3-ITD-W51, FLT3-ins595R and mock 
transduced cells were grown in the absence or presence of IL-3 for 72 hours. Viable cells 
were counted using trypan blue exclusion method. Overexpression of the point mutant FLT3-
ins595R, but not FLT3-WT induced IL-3 independent growth in Ba/F3 cells (Figure 
4.1.4.3a). In detail, the growth rate of FLT3-ins595R was 40% compared to cells expressing 
the FLT3-ITD-W51 construct, which served as a positive control.  
 
 
Figure 4.1.4.3a: Duplication of single arginine 595 in FLT3 induce IL-3 independent growth in Ba/F3 cells:  
Ba/F3 cells stably transduced with FLT3-WT, FLT3-ITD-W51, FLT3-ins595R or mock transduced cells were seeded at a 
density of 4 x 104 cells/ml in the absence or presence of IL-3. Viable cells were counted after 72 hours by trypan blue 
exclusion. The growth of cells with IL-3 was defined as 100% (control). Standard error of the mean calculated from three 
independent experiments is shown. 
 
Similar results were obtained for cells expressing FLT3-ins597RE and FLT3-ins597REY. 
The mutants FLT3-ins597RE and FLT3-ins597REY showed a growth rate of 49% and 58% 
when compared to the growth rate of FLT3-ITD (Figure 4.1.4.3b), suggesting that 
duplication of additional amino acids along with arginine assist in increasing the 
transforming potential of FLT3-ITDs.  
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Figure 4.1.4.3b: Addition of AAs to duplicated R595 increases the transforming potential of FLT3 in 
Ba/F3 cells: Ba/F3 cells stably transduced with FLT3-WT, FLT3-ITD-W51, FLT3-WT-ins595R, FLT3-WT-
ins596RE, FLT3-WT-ins587REY or mock transduced cells were seeded at a density of 4 x 104 cells/ml in the 
absence or presence of IL-3 . Viable cells were counted after 72 h by trypan blue exclusion. The growth of cells 
with IL-3 was defined as 100% (control). Standard error of the mean calculated from three independent experiments is 
shown. 
 
Quite interestingly, the cells expressing the FLT3-insEY construct that do not have a 
duplication of arginine, showed a factor independent growth but it induced only a 15% 
growth rate compared to cells grown in the presence of IL-3 (Figure 4.1.4.3c). 
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Figure 4.1.4.3c: Duplication of AAs next to R595 in FLT3 induces a very weak IL-3 independent growth 
in Ba/F3 cells: Ba/F3 cells stably transduced with FLT3-WT, FLT3-ITD-W51, FLT3-ins595R, FLT3-WT-
ins597EY or mock transduced cells were seeded at a density of 4 x 104 cells/ml in the absence or presence of 
IL-3. Viable cells were counted after 72 hours by trypan blue exclusion. The growth of cells with IL-3 was 
defined as 100% (control). Standard error of the mean calculated from three independent experiments is shown. 
 
4.1.4.4 Stimulation of FLT3 arginine insertion mutants show hyperproliferation upon 
stimulation with FL. 
Progenitor cells expressing FLT3 have been shown to grow upon stimulation by FL in vitro 
(Zheng et al., 2004). It has been shown in bone marrow and AML blasts that both FL and 
FLT3 are co-expressed. To check whether the autonomous growth of the FLT3 insertion 
mutants can be further stimulated by exogenous FL, Ba/F3 cells expressing FLT3-WT, 
FLT3-ITD-W51, FLT3-ins595R, FLT3-ins596RE, FLT3-ins597EY, FLT3-ins597REY or 
mock transduced cells were grown in the absence or presence of 60 ng of FL for 72 hours. 
All the mutants showed hyperresponsiveness in growth upon stimulation. The prolefaration 
of  FLT3-ins595R was 54%, FLT3-ins596RE 65%, FLT3-ins597EY 35%, and FLT3-
ins597REY  70% when compared to FLT3-WT which showed a growth of 22% (Figure 
4.1.4.4).  
 
 
Figure 4.1.4.4. Insertion mutants of AA595-597 show hyperproliferation upon stimulation with FL:  
Ba/F3 cells stably transduced with FLT3-WT, FLT3-ITD-W51, FLT3-ins595R, FLT3-WT-ins597EY or mock 
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transduced cells were seeded at a density of 4 x 104 cells/ml in the absence or presence of FL (60ng/ml). Viable 
cells were counted after 72 hours by trypan blue exclusion. The growth of cells with IL-3 was defined as 100% 
(control). Standard error of the mean calculated from three independent experiments is shown. 
 
4.1.4.5 A single R595 duplication causes the activation of STAT5 
FLT3 has been shown to activate three important pathways upon stimulation with FL i.e. 
STAT5, AKT and MAPK pathway (Brandts et al., 2005; Hayakawa et al., 2000; Srinivasa 
and Doshi, 2002; Zhang and Broxmeyer, 1999; Zhang et al., 2000; Zhang et al., 1999). All 
these three pathways have been shown to be constitutively activated in FLT3-ITDs. All three 
pathways have been found to be responsible for the transforming potential, but STAT5 has 
been found to be the most important signaling pathwy in FLT3-ITD transformed cells. These 
pathways regulate the genes, which are responsible for apoptosis, proliferation and early 
cytokine signalling like CyclinD1, CyclinD2, BclXl, c-Myc, SHP2, and PIM-1 (Benekli et 
al., 2003; Brandts et al., 2005; Gouilleux-Gruart et al., 1996; Kim et al., 2005; Lilly and 
Kraft, 1997; Mizuki et al., 2000; Scheijen et al., 2004; Vander Heiden et al., 1997). 
 
To investigate the activation of the STAT5 signaling pathway, we prepared crude cell 
lysatesof serum starved Ba/F3 cells transduced with either vector control(MIY), FLT3WT, 
FLT3-ITD-W51, FLT3-ins595R, FLT3-ins597EY, FLT3-ins597RE and FLT3-ins597REY. 
Lysates were analyzed by immunoblotting with a specific antibody against phospho-STAT5. 
We could clearly demonstrate that the expression of FLT3-ins595R, FLT3-ins597EY, FLT3-
ins597RE and FLT3-ins597REY led to increased phosphorylation at position 694 of STAT5 
compared to FLT3-WT (Figure 4.1.4.5A). In accordance with the proliferation data, the 
FLT3-ins597EY mutant showed a significantly weaker STAT5 activation (Figure 4.1.4.5A). 
Densitometric analysis of the western blots was done to check for the ratio of protein 
phosphorylated in comparision to total protein. This ratio revealed that all the mutants FLT3-
ins595R, FLT3-ins597RE and FLT3-ins597REY showed a phosphorylation of 6-11% 
(Figure 4.1.4.5B) when compared to FLT3-ITD (14%) (Figure 4.1.4.5B). The mutant FLT3-
ins597EY showed a phosphorylation of 4.8% (Figure4.4.5B) which was in accordance with 
the proliferation data. All the mutants showed activation of the MAPK and AKT but no 
significant difference was seen between the mutants. 
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4.1.4.5: A single R595 duplication causes the activation of STAT5: (A) Western blot showing the 
autoactivation of STAT5 in the mutants FLT3-ins595R, FLT3-ins597EY, and FLT3-ins597REY, FLT3-ITD-
W51 when compared to FLT3-WT in the unstimulated cells. FLT3-WT-ins595R, FLT3-WT-ins597EY, and 
FLT3-WT-ins597REY, FLT3-WT-ins596RE, FLT3-ITD-W51, FLT3-WT or mock trandusced cell lines were 
starved for 24 hours in the presence of 0.3% FCS and stimulated with 60 ng FL/ml for 5 minutes. Crude cell 
lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoeresis (SDS-PAGE) and blotted 
on a nitrocellulose membrane. Blots were then incubated with anti-phospho-STAT5 antibody, stripped and 
reblotted with anti-STAT5 antibody. (B) Densitometric analysis of the film in panel C was used to quantify the 
ratio of phospho-STAT5 to total STAT5. 
 
 
 
 
 
 
 
 
 
 
Results 
 41
4.1.5 Deletions or substitutions of arginine 595 in the duplicated region of FLT3-ITD 
reduce transforming potential of FLT3-ITD   
 
4.1.5.1 Generation of duplicated R595 deletion/Substitution mutants  
Having shown that duplication of R595 can activate the transforming activity of FLT3 we 
asked whether duplicated R595 is necessary for the oncogenic potential of FLT3-ITD 
mutants. For this purpose, we substituted duplicated AA Arginine (R602) with the neutral 
AA alanine (FLT3-W51-R602A) and also with the negatively charged AA glutamic acid 
(FLT3-W51-R602E) (Figure 4.1.5.1) and positively charged amino acid Lysine (FLT3-W51-
R602K). Furthermore, we generated a deletion mutant of duplicated R595 (FLT3-
W51ΔR602) (Figure 4.1.5.1) and the deletion of neighbouring AAs glutamic acid (FLT3-
W51-∆E603) and AA tyrosine (FLT3-W51-∆Y604) (Figure 4.1.5.1).  
 
 
Figure 4.1.5.1: Map of sustitution/deletion mutants of duplicated R595: The Panel  shows three different 
substitution and two deletion mutants of duplicated R595 generated in two different FLT3-ITD’s (W51 and 
NPOS). The deletion mutants of duplicated E596 and Y597 in FLT3-ITD-W51 are also shown. 
 
4.1.5.2 Generation of duplicated R595 substitution/deletion mutant cell lines 
To check the overexpression of the duplicated R595 substitution and deletion mutants, Ba/F3 
cells were stably transduced with these different FLT3-W51-R602A, FLT3-W51-R602E, 
FLT3-W51-R602K, FLT3-W51ΔR602, FLT3-W51-∆E603, FLT3-W51-∆Y604, FLT3-
NPOS-∆R623 and with FLT3-WT, FLT3-ITD-W51 and FLT3-ITD-NPOS as controls. 
Transduced EYFP-positive cells were sorted by FACS on the basis of EYFP fluorescence 
and were expanded in the presence of IL-3. After expansion the positive cells were checked 
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for FLT3 expression using PE-conjugated CD135, a FLT3 specific surface antibody in FACS 
calibur.  
 
4.1.5.3 Duplicated R595 substitution by alanine or glutamine reduces the transforming 
potential 
Since arginine is a positively charged AA, and to check role of positive charge in 
transforming potential of FLT3-ITDs, we generated substituted arginine with Alanine and 
Glutamine in the background of FLT3-ITD-W51 (Figure 4.1.5.1). Overxpression of the 
mutants FLT3-W51-R602E and FLT3-W51-R602A in the absence of IL3 medium showed a 
factor independent growth. The transforming potential of the FLT3-W51-R602A and FLT3-
W51-R602E reduced when compared to the unmanipulated FLT3-ITD-W51 (Figure 4.1.5.3). 
In detail, growth rate of FLT3-W51-R602A and FLT3-W51-R602E was ~ 46% when 
compared to +IL3 growth. In contrast unmanipulated FLT3-ITD-w51 showed a growth rate 
92% of +IL3 growth (Figure 4.1.5.3). 
 
 
 
4.1.5.3: Substitution of duplicated R595 by alanine or glutamic acid in FLT3-ITD-W51 reduces the 
transforming potential: Ba/F3 cells stably transduced with FLT3-WT, FLT3-ITD-W51, FLT3-W51-R602A, 
FLT3-W51-R602E, or mock transduced cells were seeded at a density of 4 x 104 cells/ml in the absence or 
presence of IL-3. Viable cells were counted after 72 hours. The growth of cells in the presence of IL-3 was 
defined as 100% (control). Standard error of the mean calculated from three independent experiments is 
indicated. 
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4.1.5.4 Deletion of R595 in FLT3-ITDs shows reduction in the transforming potential. 
Since 23% of the patients with FLT3-ITDs don’t have any R595 duplications. Hence, we 
wanted to check the transforming potential of FLT3-ITDs without Arginine. Overexpression 
of the deletion mutant FLT3-W51-∆R602 in –IL3 medium showed factor independent 
growth of cells, but the growth of cells was drastically reduced by ~70% when compared to 
+IL3 growth and FLT3-ITD-W51 (Figure 4.1.5.4A). To further validate this finding, we 
generated a deletion mutant of duplicated R595 (FLT3-ITD-NPOS∆623R) in a structurally 
different FLT3-ITD construct, FLT3-ITD-NPOS that contains a 28AA duplicated sequence 
(CSSDNEYFYDFREYEYDLKWEFPRENL) inserted between AA611/612 of FLT3-WT 
(Figure 4.5.1). Expression of the deletion mutant (FLT3-ITD-NPOS∆623R) showed a similar 
phenotype compared to FLT3-W51ΔR602 with a reduction of ~70% of its proliferative 
capacity when compared to the FLT3-ITD-NPOS construct (Figure 4.1.5.4B).  
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4.15.4: Deletion of duplicated R595 in two differnt FLT3-ITDs show significant reduction in the 
transforming potential: (A) Ba/F3 cells stably transduced with FLT3-WT, FLT3-ITD-W51, FLT3-W51-
∆R602, or mock transduced cells were seeded at a density of 4 x 104 cells/ml in the absence or presence of IL-3. 
Viable cells were counted after 72 h. The growth of cells with IL-3 was defined as 100% (control). Standard 
error of the mean calculated from three independent experiments is indicated. (B) Proliferation curves of 
deletion mutant of duplicated R595 made in a different FLT3-ITD (FLT3-ITD-NPOS).  
 
 
4.1.5.5 Duplicated R595 substitution by lysine has no effect on the transforming 
potential 
Having shown that the positively charged arginine plays an important role in the 
transforming potential of FLT3-ITDs, we asked if the duplicated arginine can be replaced 
with another positively charged amino acid. Hence, we substituted the duplicated arginine 
with the positively charged AA lysine (FLT3-W51-R602K) (Figure 4.1.5.1). Overexpression 
of FLT3-W51-R602K in Ba/F3 cells induced factor independent growth and did not show 
any reduction of the transforming potential when compared to FLT3-ITD-W51 (Figure 
4.1.5.5). These data clearly show that the positive charge of the AA (arginine or lysine) plays 
a crucial role in the transforming potential of FLT3-ITD’s. 
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4.1.5.5: Substitution of duplicated R595 with onother positively charged AA lysine shows no reduction in 
the transforming potential of FLT3-ITD-W51: Ba/F3 cells stably transduced with FLT3-WT, FLT3-ITD-
W51, FLT3-W51-∆R602, FLT3-W51-R602K or mock transduced cells were seeded at a density of 4 x 104 
cells/ml in the absence or presence of IL-3. Viable cells were counted after 72 hours. The growth of cells in the 
presence of  IL-3 was defined as 100% (control). Standard error of the mean calculated from three independent 
experiments is indicated.  
 
4.1.5.6 Deletion of duplicated AA E596 and Y597 has no effect on transforming 
potential of FLT3-ITDs. 
Patient data have shown that AAs E596 and Y597 are the next frequently duplicated AAs 
other than R595 in 73 and 74% of patients respectively. Hence to check the effect of 
duplicated AAs E596 and AA E597, we generated deletion mutants FLT3-W51-∆E603 and 
FLT3-W51-∆Y604 in FLT3-ITD-W51 (Figure 4.1.5.1). Over expression of mutants FLT3-
W51-∆E603 and FLT3-W51-∆Y604 showed factor independent growth, but there was not 
significant reduction in the transforming potential when compared to FLT3-ITD-W51 
(Figure 4.1.5.6). FLT3-W51-∆E603 and FLT3-W51-∆Y604 showed a transforming potential 
of 83% and 76% when compared to FLT3-ITD-W51.  
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4.1.5.6: Deletion of neighbouring AAs next to duplicated R595 in FLT3-ITD-W51 show no significant 
reduction in the transforming potential: Ba/F3 cells stably transduced with FLT3-WT, FLT3-ITD-W51, 
FLT3-W51-∆E603, FLT3-W51-∆Y604 or mock transduced cells were seeded at a density of 4 x 104 cells/ml in 
the absence or presence of IL-3. Viable cells were counted after 72 hours. The growth of cells in the presence of 
IL-3 was defined as 100% (control). Standard error of the mean calculated from three independent experiments 
is indicated.  
 
 
4.1.5.7 Stimulation of R595 deletion/substitution mutants shows hyperproliferation 
upon stimulation with Flt3 ligand. 
To simulate an in vivo situation, where both FLT3 and FLT3 ligand are coexpressed in 
leukemic blast cells, we stimulated Ba/F3 cells expressing all the mutants FLT3-W51-
R602A, FLT3-W51-R602E, FLT3-W51-R602K, FLT3-W51ΔR602, FLT3-W51-∆E603, 
FLT3-W51-∆Y604 and FLT3-NPOS-∆R623 along with the controls FLT3-WT, FLT3-ITD-
W51 and FLT3-ITD-NPOS FL (60 ng/ml). All the mutants showed hyperproliferation of the 
cells upon stimulation with FL (Figure 4.1.5.7). In detail FLT3-W51-R602A, FLT3-W51-
R602E, FLT3-W51-R602K, FLT3-W51ΔR602, FLT3-W51-∆E603, FLT3-W51-∆Y604 and 
FLT3-NPOS-∆R623 showed a hyperproliferation of 72%, 62%, 97%, 42%, 96%, 84% and 
42% respectively ( Figure 4.1.5.7). 
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4.1.5.7: Deletion/susbstitution mutants of duplicated R595 show hyperproliferation upon stimulation with 
FL:  Ba/F3 cells stably transduced with FLT3-WT, FLT3-ITD-W51, FLT3-W51-R602A, FLT3-W51-R602E, 
FLT3-W51-R602K, FLT3-W51ΔR602,FLT3-W51-∆E603, FLT3-W51-∆Y604 or mock transduced cells were 
seeded at a density of 4 x 104 cells/ml in the absence or presence of FL (60ng/ml). Viable cells were counted 
after 72 hours. The growth of cells with IL-3 was defined as 100% (control). Standard error of the mean 
calculated from three independent experiments is indicated.  
 
4.1.5.8 FLT3-ITDs duplicated R595 substitution/deletion mutants show a reduced 
capacity to activate STAT5 compared to FLT3-ITDs 
To investigate the activation of the STAT5, AKT and MAPK signalling pathways we 
prepared crude cell lysates of serum starved Ba/F3 cells, transduced with either vector 
control (MIY), FLT3-WT, FLT3-ITD-W51, FLT3-ITD-NPOS, FLT3-W51-R602A, FLT3-
W51-R602E, FLT3-W51-R602K, FLT3-W51-∆R602, FLT3-W51-∆E603, and FLT3-NPOS-
∆R623. All the mutants FLT3-W51-R602A, FLT3-W51-R602E, FLT3-W51-∆R602, and 
FLT3-NPOS∆623R in Ba/F3 cells showed reduced phosphorylation of the STAT5 compared 
to non-manipulated FLT3-ITD constructs, (Figure 4.1.5.8a,b). STAT5, AKT and MAPK 
activation of FLT3-W51-R602K was similar to the FLT3-ITDs (Figure 4.1.5.8a, b). Thus, the 
activation of the most important signalling pathways downstream of FLT3, STAT5, AKT 
and MAPK are downregulated in FLT3-W51-R602A, FLT3-W51-R602E, FLT3-
W51∆602R, and FLT3-NPOS∆623R, but not in FLT3-W51-R602K expressing cells and 
correlates with IL-3 independent growth. 
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Figure 4.15.8a: The constitutive STAT5 activation is reduced in substitution/deletion mutants of 
duplicated R595: FLT3-WT, FLT3-ITD-W51, FLT3-ITD-NPOS, FLT3-W51-R602A, FLT3-W51-R602E, 
FLT3-W51-R602K, FLT3-W51-∆R602, FLT3-W51-∆E603 and FLT3-NPOS-∆R623 expressing cells were 
starved for 24 hours in the presence of of 0.3% FCS. Blots were incubated with anti-phospho-STAT5 antibody, 
stripped and reblotted with anti-STAT5 antibody. 
 
 
Figure 4.1.5.8b: The constitutive AKT and MAPK activation is reduced in substitution/deletion mutants 
of duplicated R595: FLT3-WT, FLT3-ITD-W51, FLT3-ITD-NPOS, FLT3-W51-R602A, FLT3-W51-R602E, 
FLT3-W51-R602K, FLT3-W51-∆R602, FLT3-W51-∆E603 and FLT3-NPOS-∆R623 expressing cells were 
starved for 24 hours in the presence of of 0.3% FCS. Blots were incubated with anti-phospho-AKT and anti-
phospho-MAPK antibodies, stripped and reblotted with anti-AKT and anti-MAPK antibodies. 
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4.1.5.9 The substitution/deletion arginine mutants of FLT3-ITDs are sensitive to the 
FLT3 PTK inhibitor PKC412 
PKC412 (Novartis), an inhibitor initially discovered as an inhibitor of protein kinase C, was 
found to block the phosphorylation and activity of FLT3-WT and mutant FLT3-receptors 
(Stone et al., 2005; Weisberg, 2002). The inhibitory activity of PKC412 against the arginine 
mutants of FLT3-ITDs was analyzed by treating the FLT3-W51-R602A, FLT3-W51-R602E, 
FLT3-W51∆602R, and FLT3-NPOS∆623R expressing cells with different concentrations of 
PKC412 ranging from 1 to 100 nM. PKC412 showed a strong growth inhibitory effect on 
FLT3-W51-R602A, FLT3-W51-R602E, FLT3-W51-R602K, FLT3-W51∆602R, and FLT3-
NPOS∆623R receptors expressing cells in the absence but not in the presence of IL-3. The 
IC50 of PKC412 was significantly lower in arginine substitution/deletion mutants (0.6-1 nM) 
compared to FLT3-ITD mutants (4 nM) (Table 4.1.5.9).  
 
 
 
 
 
 
 
 
Table 4.1.5.9: IC50 for PKC412 values in different FLT3-ITD arginine mutants: Ba/F3 cells expressing 
FLT3-WT, FLT3-ITD-W51, FLT3-ITD-NPOS, FLT3-W51-R602A, FLT3-W51-R602E, FLT3-W51-R602K, 
FLT3-W51-∆R602 and FLT3-NPOS-∆R623 seeded at a density of 4 X104 cells/mL in the absence or presence 
of different concentrations of PKC412 (0 to 100 nM) and counted after 72 hours.  All cell lines were also 
cultured in the presence of IL-3 and 100 nM PKC412 to confirm nontoxicity of PKC412 to Ba/F3 cells. The IC50 
was calculated from three independent experiments (IC50 is defined as the concentration of inhibitor required to 
induce a growth reduction of 50% compared to the cells grown in the absence of inhibitor). 
 
 
 
 
 
FLT3-ITD(W51/NPOS) 4.0 nM 
FLT3-W51-R602A 0.9 nM 
FLT3-W51-R602E 0.8  nM 
FLT3-W51-R602K 4.0  nM 
FLT3-W51-∆R602 0.6  nM 
FLT3-NPOS-∆R623 0.7  nM 
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4.1.6 Deletion of wild type R595 reduces the transforming potential and activation of 
STAT5 in FLT3-ITD mutant 
 Since the duplicated arginine plays an important role for the transforming potential the 
FLT3-ITDs, we asked whether wild type R595 also has a critical role in the transforming 
capacity of FLT3-ITDs. We therefore created a deletion mutant of R595 in FLT3-ITD-W51 
(FLT3-W51-∆R595) (Figure 4.1.6.1A).  
Overexpression of the wild type arginine deletion mutant FLT3-W51-∆R595 reduced the IL-
3 independent growth by 64% when compared to FLT3-ITD-W51 (Figure 4.1.6.1B).  
 
 
         A 
 
 
 
 
 
 
                          B 
 
Figure 4.1.6.1: Deletion of wild type R595 in FLT3-ITD-W51 results in reduced transforming potential in 
Ba/F3 cells: (A) Schematic representation of wild type R595 (FLT3-W51-∆R595) deletion mutant in the FLT3-
ITD-W51 construct. (B) Ba/F3 cells expressing the FLT3-WT, FLT3-W51-∆R595, FLT3-ITD-W51 and mock 
transduced cells were seeded at a density of 4 x104 cells/ml in the absence or presence of IL-3. Viable cells were 
counted after 72 hours by trypan blue exclusion. The growth of cells with IL-3 was defined as 100% (control). 
The standard error of the mean calculated from three independent experiments is indicated. 
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These proliferation data were supported by the measurement of STAT5 activation (Figure  
4.6.2). STAT5 activation was significantly lower in the cells expressing FLT3-W51-∆R595, 
when compared to FLT3-ITD-W51. These data suggest that not only the duplicated R595 but 
also the wild type R595 plays an important role in the transforming potential and STAT5 
activation of FLT3-ITD-W51. 
 
 
Figure 4.1.6.2: Deletion of wild type R595 in FLT3-ITD-W51 results in reduced phosphoSTAT5 activation 
in Ba/F3 cells: Western blot image showing the activation of STAT5 in cells expressing FLT3-W51-∆R595 and 
FLT3-ITD-W51, when compared to FLT3-WTor mock transduced cells. Cells were starved in the presence of 
0.3% FBS for 24 hours.  Blots were incubated with anti-phospho-STAT5 antibody, stripped and reblotted with 
anti-STAT5 antibody. 
 
4.1.7 Deletion of R595 in FLT3-WT abrogates the growth of cells upon FL stimulation 
Since duplicated arginine plays an important role for the transforming potential of FLT3-
ITDs, we wanted analyse the role of the wild type arginine 595 in the signalling properties of 
the FLT3-WT. Hence we created a deletion mutant of arginine 595 in FLT3-WT (FLT3-WT-
∆R595) (Figure 4.1.7.1A). We stably transduced the pro-B cell line Ba/F3 with FLT3-WT-
∆R595, using FLT3-WT and FLT3-ITD (W51) as a control. Identical surface expression 
levels of FLT3 were confirmed by CD135 antibody staining and FACS analysis (data not 
shown).  
Overexpression of the arginine deletion mutant FLT3-WT-∆R595, did not show any –IL3 
independednt growth, but to the surprise it also did not show any growth of the cells on 
stimulation with FL, when compared to FLT3-WT (Figure 4.1.7.1B).  
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Figure 4.1.7.1: Wild type R595 deletion in FLT3 results loss FL induced growth of cells: (A) Schematic 
representation of wild type R595 (FLT3-WT-∆R595) deletion mutant in the FLT3-WT construct. (B) Ba/F3 cells 
expressing the FLT3-WT, FLT3-WT-∆R595, FLT3-WT and mock transduced cells were seeded at a density of 4 
x104 cells/ml in the absence or presence of IL-3 and FL (60ng/ml). Viable cells were counted after 72 hours by 
trypan blue exclusion. The growth of cells with IL-3 was defined as 100% (control). The standard error of the 
mean calculated from three independent experiments is indicated. 
 
 
Since it has been shown that STAT5 plays an important role in signal transduction of FLT3, 
we prepared crude cell lysates of serum starved Ba/F3 cells transduced with MIG, FLT3-WT, 
and FLT3-WT-∆R595 and Flt3-ITD-W51 acting as positive control. Lysates were analysed 
by immunoblotting with a specific antibody against phospho-STAT5. As expected we could 
not detect any STAT5 actiovation in the FLT3-WT-∆R595, when compared to FLT3-WT 
expressing cells, suggesting that arginine 595 plays important role in the STAT5 activation of 
FLT3-WT stimulated with FL (Figure 4.1.7.2). 
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Figure 4.1.7.2: Deletion of wild type R595 in FLT3-WT results in reduced phosphoSTAT5 activation in 
Ba/F3 cells: Western blot image showing the activation of STAT5 in cells expressing FLT3-WT-∆R595 and 
FLT3-WT, when compared to FLT3-WT or mock transduced cells in the absence and presence of FL (60ng/ml). 
Cells were starved in the presence of 0.3% FBS for 24 hours.  Blots were incubated with anti-phospho-STAT5 
antibody, stripped and reblotted with anti-STAT5 antibody. 
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4.2 The role of tyrosine residues in the juxtamembrane domain of FLT3 in the 
activation of FLT3-ITDs 
4.2.1 Generation of substitution mutants of juxtamembrane domain tyrosine residues  
Tyrosine residues of the juxtamembrane domain have been shown to be playing important 
role in maintaining the unphosphorylated and phosphorylated states of FLT3. But no study 
has been carried out in detail about the role of tyrosoine residues 589, 591, 597 and 599 in 
the FLT3-ITDs and theire role in transforming potential of FLT3-ITDs. For this purpose, we 
substituted the tyrosine residues 589, 591, 597 and 599 with phenyalanine as single and  
double mutants in different combinations (Figure 4.2.1). 
 
Figure 4.2.1: Map of sustitution mutants of tyrosine residues in the juxtamembrane of FLT3-ITD-
W51duplicated R595: Panel shows three different single and double combinatorial substitution mutants of 
tyrosine residues 589, 591, 597 and 599 of the juxtamebrane domain with phenylalanine made in the background 
of FLT3-ITD-W51. 
 
4.2.2 Generation of duplicated R595 substitution/deletion mutant cell lines 
To check the overexpression of the tyrosine substitution, Ba/F3 cells were stably transduced 
with FLT3-W51-Y589F, FLT3-W51-Y591F, FLT3-W51-Y597F and double substitutions 
FLT3-W51-YY589/591FF, FLT3-W51-YY589/597FF, FLT3-W51-YY589/599FF, FLT3-
W51-YY91/597FF, FLT3-W51-YY597/599FF and with FLT3-WT, FLT3-ITD-W51 as 
controls. Transduced EYFP-positive cells were sorted by FACS on the basis of EYFP 
fluorescence and were expanded in the presence of IL-3. After expansion the positive cells 
were checked for FLT3 expression using PE-conjugated CD135, a FLT3 specific surface 
antibody in FACS caliber (data not shown). 
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4.2.3 Substitution of tyrosine residues 589 and 591 in FLT3-ITD-W51 abolishes the 
transforming potential of FLT3-ITD 
Patient samples analysis, showed that in the majority of the AML patients harbouring FLT3-
ITDs, the amino acids 589 and 591 of FLT3 are not duplicated. Hence, we hypothesised that 
these residues play an important role in the transforming potential of FLT3-ITDs.  Therefore, 
we generated single substitutions of 589 (FLT3-W51-Y589F), 591 (FLT3-W51-Y591F) and 
double substitutions (FLT3-W51-YY589/91FF) with phenyalanine in the background of 
FLT3-ITD-W51 (Figure 4.2.1). Overexpression of these mutants in Ba/F3 cells showed that 
mutants FLT3-W51-Y589F and FLT3-W51-Y591F did not show any significant decrease in 
the transforming potential of FLT3-ITDs (Figure 4.2.3). In contrast, the mutant FLT3-W51-
YY589/91FF completely lost the transforming potential when compared to unmanipulated 
FLT3-ITD-W51 (Figure 4.2.3). Quite interestingly, cells expressing the double substitution 
mutant FLT3-W51-YY589/91FF also lost the ability to grow upon stimulation with FL, 
signifying the role of these residues in transforming potential of FLT3-ITDs (Figure 4.2.3).  
 
 
4.2.3: Substitution of tyrosines 589 and 591 abolishes the transforming potential of FLT3-ITD-W51: 
Ba/F3 cells stably transduced with FLT3-WT, FLT3-ITD-W51, FLT3-W51,FLT3-W51-Y589F, FLT3-Y591F, 
FLT3-W51-YY589/591FF, or mock transduced cells were seeded at a density of 4 x 104 cells/ml in the absence 
or presence of IL-3 and FL (60ng/ml). Viable cells were counted after 72 hours. The growth of cells with IL-3 
was defined as 100% (control). Standard error of the mean calculated from three independent experiments is 
indicated.  
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4.2.4 Substitution of residues 591 and 599 in combination with 589 reduces the 
transforming potential of FLT3-ITDs 
A recent study in has shown that tyrosines 589 and 599 is the phosphoryated upon 
stimulation with FL (Heiss et al., 2006). But in our hands, single substitution of tyrosine 589 
did not have any effect on transforming potential of FLT3-ITDs where as the double mutant 
FLT3-W51-YY589/91FF showed no transforming potential (Figure 4.2.1). Hence, for this 
purpose we made different double substation mutants of 589 in combination with other 
tyrosine residues 597 (FLT3-W51-YY589/97FF) and 599 (FLT3-W51-YY589/99FF). 
Overexpression of these mutants FLT3-W51-YY589/97FF and FLT3-W51-YY589/99FF in 
the IL-3 dependent Ba/F3 cells showed that these mutants gave factor independent growth to 
the cells, but the transforming potential was very weak when compared to the unmanipulated 
FLT3-ITD-W51 (Figure 4.2.4)..  
 
4.2.4: Substitution of tyrosine 589 along with tyrosines 597 and 599 reduces the transforming potential of 
FLT3-ITD expressing cells: Ba/F3 cells stably transduced with FLT3-WT, FLT3-ITD-W51, FLT3-W51, 
FLT3-W51-YY589/591FF, FLT3-W51-YY589/597FF, FLT3-W51-YY589/599FF or mock transduced cells 
were seeded at a density of 4 x 104 cells/ml in the absence or presence of IL-3 and FL (60ng/ml). Viable cells 
were counted after 72 hours. The growth of cells with IL-3 was defined as 100% (control). Standard error of the 
mean calculated from three independent experiments is indicated.  
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4.2.5 Substitution of residues 597 in combination with 591 reduces the transforming 
potential of FlT3-ITDs 
 
Having shown that when tyrosine residues 589 mutated along with 597 or 599 residue 
decreases the transforming potential of FLT3-ITD-W51, we now checked, the role of 
tyrosine residue 591, when it is mutated in combination with either 597/599. Hence, for this 
purpose we generated double substation mutants of 591 in combination with tyrosine 
residues 597 (FLT3-W51-YY591/97FF) (Figure 4.2.1). Over expression of these mutants 
FLT3-W51-YY591/97FF in the IL-3 dependent Ba/F3 cells showed that these mutants 
conferred factor independent growth to the cells, but the transforming potential was very 
weak when compared to the unmanipulated FLT3-ITD-W51 (Figure 4.2.5).  
 
 
 
 
4.2.5: Substitution of tyrosine 591 and 597 together reduces the transforming potential of FLT3-ITD: 
Ba/F3 cells stably transduced with FLT3-WT, FLT3-ITD-W51, FLT3-W51, FLT3-W51-Y591F, FLT3-Y597F, 
FLT3-W51-YY591/597FF or mock transduced cells were seeded at a density of 4 x 104 cells/ml in the absence 
or presence of IL-3 and FL(60ng/ml). Viable cells were counted after 72 hours. The growth of cells with IL-3 
was defined as 100% (control). Standard error of the mean calculated from three independent experiments is 
indicated. 
Results 
 58 
4.2.6 Substitution of residues 597 together with 599 do not affect the transforming 
potential of FlT3-ITD 
 Having shown that when tyrosine residues 589/591 mutated along with 597 or 599 residue 
decreases the transforming potential of FLT3-ITD-W51, we wanted to check if the same 
effect could be seen when we mutate the tyrosine residues 597/599.. Hence, for this purpose 
we generated double substitution mutant of 597 in combination with tyrosine residues 599 
(FLT3-W51-YY591/99FF) (Figure 4.2.1). Over-expression of these mutants FLT3-W51-
YY591/99FF in the IL-3 dependent Ba/F3 cells showed that these mutants conferred factor 
independent growth to the cells, and there was no significant decrease in the transforming 
potential when compared to the unmanipulated FLT3-ITD-W51 (Figure 4.2.6).  
 
 
4.2.6: Substitution of tyrosine 591 and 597 together reduces the transforming potential of FLT3-ITD: 
Ba/F3 cells stably transduced with FLT3-WT, FLT3-ITD-W51, FLT3-W51-YY597/599FF or mock transduced 
cells were seeded at a density of 4 x 104 cells/ml in the absence or presence of IL-3 and FL(60ng/ml). Viable 
cells were counted after 72 hours. The growth of cells with IL-3 was defined as 100% (control). Standard error 
of the mean calculated from three independent experiments is indicated. 
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5 DISCUSSION  
5.1 Arginine 595 is duplicated in patients with acute leukemias carrying internal 
tandem duplications of FLT3 and is critical for its transforming potential  
 
FLT3-ITDs are found in 20-25% of AML patients and are associated with an adverse 
prognosis. Recently, three different studies have reported conflicting results, stating the 
importance of the length of the duplication for the prognostic significance of the mutation. 
One study showed that longer duplications are associated with an unfavorable prognosis in 
patients with AML, whereas another study found the opposite (Kusec et al., 2006; Stirewalt et 
al., 2006) but a more recent study showed that the length of duplication in FLT3 has no role at 
all in the prognosis of AML patients (Ponziani et al., 2006).  Given the substantial structural 
heterogeneity of FLT3-ITD mutations, no common motifs or amino acids have been identified 
so far that is duplicated in all patients and which might play a important role in the prognosis 
of patients. Hence, we sequenced the JM region of FLT3 in 284 patients with acute leukemias 
carrying internal tandem duplications in order to identify a common signature in these ITDs. 
 
Analysis of the juxtamembrane region of FLT3-ITDs, confirms previous data showing that 
internal tandem duplications are heterogenous with respect to length. The length of the 
duplication varied from 2-68 amino acids with a median of 17 AA. In 111 patients there were 
pure tandem duplications whereas in 163 patients there were additional insertions at the start 
of duplication were found that maintained a reading frame. The analysis of single residues 
within the duplicated region showed that R595 was the single most frequently duplicated AA 
in 77% of the patients, followed by Y597 in 73%, F594 and E596 in 71% of all patients. In 
95% of the patients at least one amino acid of the stretch between amino acids 591-599 was 
duplicated. A detailed statistical analysis of AA combinations from 1 to 30 AA in the 
duplicated regions showed that, although there is no central motif common in all patients, the 
site of insertion (mutational hotspot) is frequently located in or around the Y-rich strech 
region from AA 591 to 599 (YVDFREYEY) of FLT3. R595 is duplicated in 77% of the 
patients followed by a combination of EY (E596 and Y597) in 70% of patients. In vitro 
studies showed that duplication of R595 in FLT3 is able to confer factor independent growth 
to Ba/F3 cells and led to activation of STAT5. Substitution of the duplicated R595 with 
alanine (R602A) or glutamic acid (R602E) in a representative FLT3-ITD-W51 construct 
showed a significant reduction in the transforming potential of FLT3-ITD-W51. In contrast, 
Discussion 
 60 
substitution of the duplicated R595 with the positively charged AA (R602K) did not alter the 
transforming potential of cells compared to FLT3-ITD-W51 construct.  
 
Statistical analysis of our data showed that R595 is the most frequently duplicated single AA, 
Moreover, the analysis of patients with the shortest duplications showed that R595 was 
duplicated in 84% of these patients. Interestingly, the shortest duplication found in our cohort 
was R595/E596 duplication. This prompted us to check if a single R595 duplication was 
sufficient to confer factor independent growth to Ba/F3 cells. In vitro, duplication of a single 
AA, R595 (FLT3-ins595R) was sufficient to activate the transforming potential of FLT3. 
Previous studies have shown that factor-independent growth in vitro and myeloproliferative 
disease can be caused by FLT3-ITD in transgenic mice and murine bone marrow 
transplantation model (Ihle et al., 1995; Kelly et al., 2002a). The weak transforming 
phenotype of FLT3-ins595R could be attributed to a slight disturbance in the autoinhibitory 
conformation of the JM region caused by a single amino acid insertion. Similar results were 
reported by our group on point mutations in the JM region found in AML patients that have a 
weak transforming potential, when compared to FLT3-ITDs (Reindl et al., 2006). Addition of 
amino acids next to arginine, (FLT3-ins596RE, FLT3-ins597REY) increased the transforming 
potential when compared to FLT3-ins595R. Moreover, FLT3-ITD mutant lacking the R595 
duplication, i.e. FLT3-ins595EY showed a weak transforming potential when compared to 
FLT3-ins595R, FLT3-ins596RE, FLT3-ins597REY and FLT3-ITD-W51. These data clearly 
show that the duplicated R595 plays a critical role for the transforming potential of FLT3-
ITDs. Activation of FLT3 by FLT3 ligand (FL), leads to receptor dimerization and 
transphosphorylation of specific tyrosine residues, (Turner et al., 1996) which further 
activates the downstream signalling pathways including STAT5, Ras/mitogen-activated 
protein kinase (MAPK), and phosphatidylinositol 3-kinase (PI3K)/AKT pathways (Srinivasa 
and Doshi, 2002; Zhang and Broxmeyer, 1999; Zhang and Broxmeyer, 2000; Zhang et al., 
2000; Zhang et al., 1999). Ba/F3 cells expressing FLT3-ins595R, FLT3-ins597EY, FLT3-
ins596RE, FLT3-ins597REY showed hyperresponsiveness to FLT3 ligand, with a 1.5 to 3 
times higher proliferation rate compared to FLT3-WT cells. This experimental setting 
probably reflects the in vivo situation, as it has been found that FL is coexpressed in AML 
blasts (Zheng et al., 2004).  
 
FLT3-ITDs mutants are strong activators of STAT5 (Rocnik et al., 2006; Spiekermann et al., 
2003), MAPK/ERK1/2 (Hayakawa et al., 2000) and AKT (Brandts et al., 2005; Mizuki et al., 
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2000; Scheijen et al., 2004). STAT5 has been shown  to be activated in blasts of 20-80% of 
patients with AML (Benekli et al., 2003; Gouilleux-Gruart et al., 1996; Hayakawa et al., 
2000). Previous studies have also shown that these pathways regulate the expression of early 
cytokine genes like PIM-1 (Kim et al., 2005; Lilly and Kraft, 1997), FOXO proteins (Scheijen 
et al., 2004)   and Bcl-xl (Vander Heiden et al., 1997), which are responsible for cell survival 
and growth, and leads to tumour development and progression. In accordance with the 
proliferation data, all the mutants FLT3-ins595R, FLT3-ins596RE, FLT3-ins597REY and 
FLT3-ins597EY showed activation of STAT5, but to a lesser degree compared to the FLT3-
ITD-W51 mutant. All the mutants showed activation of MAPK and AKT, but there was no 
notable difference in the activation level in all the mutants. 
 
Determination of the crystal structure of FLT3-WT has shown that the JM can be divided into 
three parts (Griffith et al., 2004). The JM binding motif (JM-B) acts as an autoinhibitory 
domain, by preventing the rotation of the N lobe towards the C lobe of the tyrosine kinase 
domain (TKD) to generate the activated kinase fold, whereas the JM switch motif (JM-S) that 
lies next to JM-B provides a rigid and properly oriented scaffold for the interposition of 
tyrosines 589 and 591 between the JM-S and the C lobe of the kinase. FLT3-ITDs are 
frequently found in the JM zipper region (JM-Z) that aligns and maintains the JM-S in the 
proper orientation during and after the transition between activated and inactive states of 
FLT3. It is hard to predict the mechanisms by which these FLT3-ITDs change the 
conformation of the FLT3 protein, but it is hypothesized that the duplications offset the 
position of the JM-S in the FLT3 structure (Griffith et al, 2004). This results in disturbing or 
preventing the optimal orientation of JM-S as it tries to position the JM-B in its binding site. 
Since FLT3-ins597EY showed a transforming potential 2-4 times lower than FLT3-ins595R, 
FLT3-ins596RE and FLT3-ins597REY, we hypothesized that the positive charge of R595 
might be involved in forming crucial interactions with other AAs. These new interactions 
might not only disrupt the autoinhibitory loop formed by JM-B, but also promote higher 
tyrosine phosphorylation by rendering the JM domain more accessible for 
autophosphorylation.  
 
To analyze whether the positive charge of the duplicated R595 has any role for the oncogenic 
potential of FLT3-ITDs, we generated substitution mutants of the duplicated R595 with an 
aliphatic AA, alanine (FLT3-W51-R602A), and a negatively charged AA, glutamic acid 
(FLT3-W51-R602E) as well as a deletion mutant of the duplicated R595 (FLT3-W51-∆R602) 
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in the strongly transforming FLT3-ITD-W51.  All mutants showed factor independent growth 
in Ba/F3 cells, but the transforming potential of these mutants was reduced by 55%-70% 
compared to FLT3-ITD-W51. The same degree of reduction was seen by deleting the 
duplicated R595 (FLT3-NPOS-∆R623) in another FLT3-ITD (FLT3-ITD-NPOS) construct. 
Interestingly, there was no effect on the transforming potential when duplicated R595 was 
replaced by another positively charged AA, e.g. lysine (FLT3-W51-R602K). Deletion of the 
AA adjacent to arginine in FLT3-ITD-W51 (FLT3-W51∆E603) did not significantly reduce 
the transforming potential of FLT3-ITD-W51, confirming that the positive charge of the 
duplicated R595 plays an important role for the transforming potential of FLT3-ITDs.  
All deletion and substitution mutants of wild type and duplicated R595 in FLT3-ITDs (W51 
and NPOS) showed a reduction in the activation of STAT5, MAPK and AKT pathways 
except for the FLT3-W51-R602K suggesting that the positive charge of duplicated R595 has 
an essential role in the activation of these pathways.  
 
The hypothesis that the positive charge of arginine plays an important role in the transforming 
potential of FLT3-ITD was further confirmed by the deletion of the wild type R595 in the 
FLT3-ITD-W51 ((Flt3-W51-∆R595). Deletion of wild type R595 decreased the transforming 
potential of FLT3-ITD by 64% which was in consonance to STAT5 reduction in this cell line.  
 
Since the positive charge of both wild type and duplicated R595 had a strong influence on the 
transforming potential of FLT3-ITD, we hypothesised that R595 must also have an important 
role in the activation of FLT3-WT by FL. Deletion of R595 in FLT3-WT (FLT3-WT-∆R595) 
and expression in Ba/F3 cells nearly abolished the growth of cells (15%) and STAT5 
activation upon stimulation with FL, when compared to FLT3-WT(100%). This suggests that 
positively charged R595 has important role in the activation of STAT5 signalling which leads 
to growth and proliferation of cells. 
 
Our results clearly show that R595 is duplicated in 77% of the patients with FLT3-ITDs and 
plays a critical role for the transforming potential of FLT3-ITD mutants. For the first time, we 
have shown at the molecular level in vitro, that not only the length, but duplication of R595 is 
neccessary for the transformation of hematopoietic cells by FLT3-ITD mutants. 
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5.2 The role of tyrosine residues in the juxtamembrane domain of FLT3 in the 
activation of FLT3-ITDs 
Resolving the crystal structure of FLT3-WT (Griffith et al., 2004), has shown that the tyrosine 
rich juxtamembrane region of FLT3 acts as a autoinhibitory loop in the inactivated state. 
Previous studies of c-KIT JM domain in controlling receptor phosphorylation was well 
examined by generating a series of mutant c-KIT constructs with single alanine substitutions 
for residues Methionine-552 through Isoleucine-563 (Ma et al., 1999). This region included a 
putative-helix and most of the mutated residues found in gastrointestinal stromal tumors and 
in mastocytomas. This work demonstrated that the Y553F mutant showed receptor 
autophosphorylation but that the E561A mutant impaired ligand-induced phosphorylation. 
The tyrosine-rich stretch of the FLT3-JM domain is predicted as a putative-helix, though it 
lies downstream of the region analysed in c-KIT. It is, therefore, conceivable that the tyrosine-
rich stretch exerts inhibitory effects on spontaneous phosphorylation. In addition, since 
several SH2-containing molecules are reportedly recruited to tyrosine residues of the JM 
domain in other Class III RTKs, we examined the role of tyrosine residues (Y589, Y591, 
Y597 and Y599) in the JM domain in the activation of FLT3-ITDs. In FLT3-WT, these 
tyrosine  residues have been shown to be important for the FL-dependent activation, because 
4F-FLT3-expressing (four tyrosines 589, 591,597,599 substituted with phenyalanine) 32D 
cells could not proliferate with FL alone and FLT3 was not tyrosine-phosphorylated even 
after FL-stimulation (Kiyoi et al., 2002).  
 
Analysis of the FLT3 juxtamembrane region in 284 patients carrying FLT3-ITDs showed that 
in the majority of the patients the tyrosines residues 589 and 591 were not duplicated. Hence 
we hypothesised that these residues might have important role for the transforming potential 
of FLT3-ITDs. Therefore we substituted the Y589 (FLT3-W51-Y589F) and Y591 (FLT3-
W51-Y591F) with phenylalanine in the background of FLT3-ITD-W51. Expression of the 
substitution mutants in Ba/F3 cells did not show any effect in the transforming potential of 
FLT3-ITDs. But, simultaneous substitution of Y589 and 591 (FLT3-W51-YY589/591FF) in 
FLT3-ITD-W51, totally abrogated the transforming potential of FLT3-ITD when expressed in 
Ba/F3 cells. The mutant FLT3-W51-YY589/591FF also did not show any growth of cells 
when stimulated with FL. These results suggest that these residues might be acting as 
phosphorylation sites and enable the binding of downstream signaling molecules. The 
juxtamembrane tyrosine residues analogous to 589 and 591 in other members of related 
receptor tyrosine kinases have also been examined for their role in kinase activation. In 
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PDGFRb the tyrosine to phenylalanine mutations of Y579 and Y581 resulted in a significant 
decrease in kinase activity to varying degrees dependent on cell type (Baxter et al., 1998; 
Drummond-Barbosa et al., 1995; Mori et al., 1993; Vaillancourt et al., 1995).  In addition, 
phenylalanine substitutions of the corresponding juxtamembrane tyrosines in c-kit (Kimura et 
al., 2004)  and CSF-1R (Rohde et al., 2004) also impaired kinase activity.  
 
Y589 and Y591 were also attractive candidate residues that might account for the signal 
transduction differences between FLT3-ITD and FLT3-WT in that they are localized to the 
juxtamembrane domain that harbors the ITD mutation. Determination of the crystal structure 
of FLT3-WT has indicated that the function of the JM switch motif (JM-S) is to provide a 
rigid and properly oriented framework for the interposition of tyrosines 589 and 591 between 
the JM-S and the C lobe of the kinase (Griffith et al., 2004). These finding suggest that it may 
be possible that ITDs within the JM domain of FLT3 result in the loss of structure leading to 
constitutive activation of the kinase and exposure of Y589 and Y591 via release from the JM-
S interface with the C loop might subsequently enable phosphorylation and engagement of 
STAT5.  
To check if other tyrosine residues 597 and 599 have any role in the transforming potential 
FLT3 we generated different combination mutants of 597 and 599 with 589 and 591. 
Substitution mutants of Y589 in combination with Y597 (FLT3-W51-YY589/597FF) and 
Y599 (FLT3-W51-YY589/599FF) when expressed in Ba/F3 cells  showed a factor 
independent growth, but the transforming potential was reduced by nearly 70-80% and were 
able to show hyperproliferation upon stimulation with FL. Similar result was found with 
substitution mutant of Y591 in combination with  Y597 (FLT3-ITD-YY591/597FF). These 
results suggest that the combination of tyrosine residues 589 and 591 is critical for the 
transforming potential of FLT3-ITDs. 
 
In conclusion, we have identified specific tyrosine residues that are required for the 
transforming potential of FLT3-ITDs. Our data provide important insights into the molecular 
mechanisms of FLT3 activation by oncogenic mutation in AML.  
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6 SUMMARY  
Activating mutations in the juxtamembrane domain of FLT3 (FLT3-internal tandem 
duplications, FLT3-ITDs) represent the most frequent genetic alterations in acute myeloid 
leukemia (AML). FLT3-internal tandem duplications (FLT3-ITDs) are a heterogenous group 
of mutations in patients with acute leukemias that are prognostically important. To 
characterize the mechanism of transformation by FLT3-ITDs, we sequenced the 
juxtamembrane region (JM) of FLT3 from 284 patients with acute leukemias. The length of 
FLT3-ITDs varied from 2 to 42 amino acids (AA) with a median of 17 AA. The analysis of 
duplicated AAs showed that in the majority of patients, the duplications localize between AA 
591 to 599 (YVDFREYEY). Arginine 595 (R595) within this region is duplicated in 77% of 
patients. Single duplication of R595 in FLT3 conferred factor-independent growth to Ba/F3 
cells and activated STAT5.  Moreover, deletion or substitution of the duplicated R595 in two 
FLT3-ITD constructs as well as the deletion of wildtype-R595 in FLT3-ITD substantially 
reduced the transforming potential, pointing to a critical role of the positive charge of R595 in 
stabilizing the active confirmation of FLT3-ITDs. Deletion of R595 in the FLT3-WT 
inhibited the growth of cells upon FL stimulation and the STAT5 activation.  
 
In this study we could also show that the tyrosine residues 589 and 591 of the FLT3-ITDs 
could be important phosphorylation sites and are very crucial for the activation of FLT3-
ITDs. Simultaneous substitution of these two tyrosine residues with phenyalanine showed 
complete inhibition of the transforming potential of FLT3-ITDs and STAT5 activation. The 
substitution of tyrosine residues 597 and 599 did not show any effect on the transforming 
potential of FLT3-ITDs, supporting the previous hypothesis that these tyrosines may be only 
important to maintain the integrity of FLT3-WT in its inactive state. 
Our data provide important insights into the role of the juxtamembrane domain in the 
mechanism of transformation by FLT3-ITDs.  
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7 Zusammenfassung 
Aktivierende Mutationen in der juxtamembranösen Domäne von FLT3 (FLT3-
Längenmutationen, FLT3-LM) sind die häufigsten genetischen Alterationen in der akuten 
myeloischen Leukämie (AML). FLT3-interne Tandemduplikationen sind eine heterogene 
Gruppe von Mutationen in Patienten mit akuten Leukämien, die von prognostischer 
Bedeutung sind. Um den Mechanismus der Transformation durch FLT3-ITDs zu 
charakterisieren, haben wir die juxtamembranöse Domäne von FLT3 von 284 Patienten mit 
akuten Leukämien sequenziert. Die Länge der FLT3-ITDs variierte von 2 bis 42 
Aminosäuren (AA) mit einer medianen Länge von 17 AA. Die Analyse der duplizierten AAs 
zeigte, dass in der Mehrheit der Patienten die Duplikationen zwischen AA 591 und 599 
(YVDFREYEY) lokalisiert sind. Arginin 595 (R595) innerhalb dieser Region ist in 77% der 
Patienten dupliziert. Die einzelne Duplikation des R595 in FLT3 führte zu wachstumsfaktor-
unabhängigem Wachstum von Ba/F3-Zellen und aktivierte STAT5. Darüber hinaus führte die 
Deletion oder Substitution des duplizierten R595 in zwei FLT3-ITD Konstrukten sowie die 
Deletion des wildtyp-R595 in FLT3-ITD zu einer signifikanten Reduktion des 
transformierenden Potentials, was auf eine kritische Rolle der positiven Ladung des R595 in 
der Stabilisierung der aktiven Konformation der FLT3-ITDs hinweist. Die Deletion des R595 
in FLT3-WT inhibierte das Wachstum der Zellen nach FL-Stimulierung und die STAT5 
Aktivierung der Zellen.  
 
In dieser Studie konnten wir weiterhin zeigen, dass die Tyrosinreste 589 und 591 der FLT3-
ITDs die Phosphorylierungsstellen sein könnten und entscheidend für die Aktivierung der 
FLT3-ITDs sind. Die gleichzeitige Substitution dieser beiden Tyrosinreste durch 
Phenylalanin führte zur vollständigen Inhibition des transformierenden Potentials der FLT3-
ITDs und STAT5 Aktivierung. Die Substitution der Tyrosinreste 597 und 599 hatte keine 
Auswirkung auf das transformierende Potential der FLT3-ITDs und unterstützt damit die 
Hypothese, dass diese Tyrosinreste möglicherweise nur für die Integrität des FLT3-WT 
Proteins in der inaktiven Konformation wichtig sind.  
 
Unsere Daten erlauben wichtige Einblicke in die Funktion der juxtamembranösen Domäne 
im Mechanismus der Transformation durch FLT3-ITDs. 
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NEOPLASIA
Arginine 595 is duplicated in patients with acute leukemias carrying internal
tandem duplications of FLT3 and modulates its transforming potential
Sridhar Vempati,1,2 Carola Reindl,1,2 Seshu Kumar Kaza,1 Ruth Kern,1,2 Theodora Malamoussi,1,2 Martin Dugas,3
Gudrun Mellert,4 Susanne Schnittger,5 Wolfgang Hiddemann,1,2 and Karsten Spiekermann1,2,4
1Clinical Cooperative Group “Leukemia”, GSF–National Research Center for Environment and Health, Munich, Germany; 2Department of Medicine III, University
of Munich-Grosshadern, Munich, Germany; 3Institute of Medical Informatics and Biomathematics, University of Münster, Münster, Germany; 4Laboratory for
Leukemia Diagnostics, University of Munich-Grosshadern, Munich, Germany; 5Munich Leukemia Laboratory, Max-Lebsche-Platz 31, Munich, Germany
FLT3–internal tandem duplications (FLT3-
ITDs) comprise a heterogeneous group of
mutations in patients with acute leuke-
mias that are prognostically important. To
characterize the mechanism of transfor-
mation by FLT3-ITDs, we sequenced the
juxtamembrane region (JM) of FLT3 from
284 patients with acute leukemias. The
length of FLT3-ITDs varied from 2 to 42
amino acids (AAs) with a median of 17
AAs. The analysis of duplicated AAs
showed that in the majority of patients,
the duplications localize between AAs
591 to 599 (YVDFREYEY). Arginine 595
(R595) within this region is duplicated in
77% of patients. Single duplication of
R595 in FLT3 conferred factor-indepen-
dent growth to Ba/F3 cells and activated
STAT5. Moreover, deletion or substitution
of the duplicated R595 in 2 FLT3-ITD
constructs as well as the deletion of wild-
type R595 in FLT3-ITD substantially re-
duced the transforming potential and
STAT5 activation, pointing to a critical
role of the positive charge of R595 in
stabilizing the active confirmation of FLT3-
ITDs. Deletion of R595 in FLT3-WT nearly
abrogated the ligand-dependent activa-
tion of FLT3-WT. Our data provide impor-
tant insights into the molecular mecha-
nism of transformation by FLT3-ITDs and
show that duplication of R595 is impor-
tant for the leukemic potential of FLT3-
ITDs. (Blood. 2007;0:000-000)
© 2007 by The American Society of Hematology
Introduction
Mutations in the FMS-like tyrosine-kinase 3 (FLT3) are one of the
most frequently found genetic alterations in patients with acute
myeloid leukemia (AML),1-13 myelodysplastic syndromes (MDSs;
10%-15%)14,15 and acute lymphoblastic leukemia (ALL; 1%-
3%).9,16,17 FLT3 belongs to the class III of receptor tyrosine kinases,
which are characterized by the presence of an extracellular
immunoglobulin-like domain, a transmembrane and the cytoplas-
mic juxtamembrane (JM) domain, and the tyrosine kinase domain
(TKD).18 The class III receptors also include KIT, FMS, PDGFRA,
and PDGFRB.19,20
Activation of FLT3 by FLT3 ligand (FL) leads to receptor
oligomerization and transphosphorylation of specific tyrosine resi-
dues,21 which activates the downstream signaling pathways includ-
ing STAT5, Ras/mitogen-activated protein kinase (MAPK), and
phosphatidylinositol 3-kinase (PI3K)/AKT.22-25 FLT3 is highly
expressed in CD34 hematopoietic progenitor cells and plays an
important role in normal hematopoiesis.26-29 Three distinct activat-
ing mutations of FLT3 in hematologic malignancies have been
reported: point mutations (FLT3-JM-PM)30,31 and internal tandem
duplications (FLT3-ITD) in the JM domain and mutations in the
tyrosine-kinase domain (FLT3-TKD).1,8,9,12,16,17,32
The crystal structure of FLT3 has shown that the JM domain
acts as an autoinhibitory domain in the inactive state.33 The JM
domain is highly conserved across all members of class III RTKs.
Hence many tumors in humans show activating mutations of JM in
class III RTKs.34-37 FLT3-ITDs, found in a majority of acute
leukemia patients, are in-frame duplications of a fragment of the
JM domain. FLT3-ITDs are highly heterogeneous and vary in
length from 2 to 68 AAs. These duplications are thought to disrupt
the autoinhibitory mechanism of FLT3 and result in constitutive
activation of the catalytic domain of FLT3. Activated FLT3 mutants
promote cell proliferation and inhibit apoptosis, leading to factor-
independent growth of murine hematopoietic cells in vitro and a
myeloproliferative phenotype in vivo.38
FLT3-ITDs are present in the leukemic blasts of 20% to 30%
of all AML patients. Recent studies have also shown that
FLT3-ITDs are found in the leukemic stem cells.39 Furthermore,
the presence of a FLT3-ITD has been recognized as an
independent poor prognostic factor in AML and is associated
with a decreased survival due to an increased relapse
rate.8,9,11,12,40-43 Several factors influence the poor prognosis seen
in AML patients harboring FLT3-ITDs (eg, a high FLT3-ITD/wild-
type ratio).9,44 A recent study has reported that the detection of
FLT3-ITD mutation in less mature progenitor populations (eg,
CD34/CD33) might be associated with drug resistance.43
In the present study, we asked whether any common duplicated
motif exists in AML patients carrying FLT3-ITDs, which might be
responsible for the transforming potential. To address this question,
we sequenced and analyzed the JM region of FLT3 from 284
patient samples with acute leukemias carrying FLT3-ITDs. We
found that the length of FLT3-ITDs varied from 2 to 42 amino acids
(AAs) with a median of 17 AAs. Duplications were localized in the
AA stretch from 591 to 599 (YVDFREYEY) of FLT3. Arginine
595 (R595), within this region, is duplicated in 77% of patients. In
vitro studies showed that both wild-type and duplicated R595 are
critical for the transforming potential of the FLT3-ITDs. These data
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provide important insight into the molecular mechanisms of
malignant transformation by FLT3-ITDs.
Patients, materials, and methods
Patients and samples. Two hundred and eighty four patients diagnosed
with acute leukemias and carrying FLT3-ITD listed in the patient data bank
of the Laboratory for Leukemia Diagnostics, University Clinic of Grosshad-
ern, Munich were used for this study. All patients gave informed consent
before entering the study. The study design adhered to the principles of the
Declaration of Helsinki and was approved by the ethics committees of the
participating institutions. Clinical and laboratory data of patients analyzed
in this study are given in Table 1. Ten patients included in this study had no
clinical data.
Reagents and cell lines. Low passage murine Ba/F3 cells were
obtained from the DSMZ (Deutsche Sammlung von Mikroorganismen und
Zellkulturen, Braunschweig, Germany) and were maintained in RPMI-1640
medium with 10% fetal bovine serum (FBS) and 10% WEHI conditioned
medium as a source of murine IL-3 when indicated. PKC412 was kindly
provided by Novartis Pharma (Basel, Switzerland).
Cell proliferation of Ba/F3 cells. Cells were seeded at a density of
4  104/mL for short-term proliferation and in the presence or absence of
IL-3 and inhibitor as indicated. Viable cells were counted at the indicated
time points in a standard hemacytometer after staining with trypan blue.
Figures show mean values and standard deviations from 3 independent
experiments unless otherwise indicated.
Antibodies. The following antibodies were used: anti-FLT3 antibody
(Sc-480; Santa Cruz, Heidelberg, Germany), anti–phospho-STAT5-Tyr694
(New England Biolabs, Frankfurt, Germany), and anti-STAT5 (sc-835;
Santa Cruz).
DNA constructs and vectors. The FLT3-ITD-W51 construct contains a
7–amino acid– duplicated sequence (REYEYDL) inserted between AAs
601/602 of human FLT3-WT, and the FLT3-ITD-NPOS contains a 28-AA–
duplicated sequence (CSSDNEYFYDFREYEYDLKWEFPRENL) in-
serted between AAs 611/612 of FLT3-WT. All FLT3 constructs were
subcloned in the MSCV-IRES-EYFP/EYFP retroviral expression vector
(kindly provided by R. K. Humphries, The Terry Fox Laboratory, Vancou-
ver, University of British Columbia).
In vitro mutagenesis. The mutants FLT3-WT-ins595R, FLT3-WT-
ins597EY, FLT3-WT-ins596RE, FLT3-WT-ins597REY, FLT3-WT-
ins591YFY, FLT3-WT-ins602KWE, and FLT3-WT-595 in the FLT3-WT;
FLT3-W51-R602A, FLT3-W51-R602E, FLT3-W51-R602K, FLT3-W51-
R602, FLT3-W51-E603, and FLT3-W51-R595 in the FLT3-ITD-W51;
and FLT3-NPOS-R623 in the FLT3-ITD-NPOS were created using the
QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA)
according to the manufacturer’s instructions. The correct sequence of all
constructs was confirmed by nucleotide sequencing.
Transient transfection of 293 cells and stable transduction of Ba/F3 cells
were performed as previously described.45
Western blot analysis was performed as previously described.45
Statistical analysis. Analysis of duplicated amino acids was performed
by PERL-programs (Version 5; http://www.perl.com). Sequences were
parsed with regular expressions. Sequence patterns were analyzed as
frequency tables of individual amino acids by position as well as frequency
tables of subsequences by position. All subsequences of length 1 to 30 were
extracted from the data set and sorted by frequency.
Results
Internal tandem duplications are located in the common motif
YVDFREYEY and include R595 in 77% of patients
The most common form of activating FLT3 mutation is an internal
tandem duplication, which occurs in 20% to 25% of patients with
AML1,3,4 and 5% to 10% of patients with myelodysplastic syn-
dromes (MDSs).1,3,4 Since these duplications are of variable length
and location, we aimed to identify a common duplicated motif in
the FLT3-JM region.
The cDNA of 284 unselected patient samples carrying FLT3-
ITDs was analyzed. Nucleotide sequencing of the JM region
showed that 118 patients expressed pure tandem duplications,
whereas 166 patients carried additional insertions always maintain-
ing the reading frame (data not shown). The length of duplications
varied from 2 AAs to 42 AAs, with the median length being 17
AAs. In 95% of the patients, at least one AA within the stretch
Y591 to Y599 (YVDFREYEY) was duplicated (data not shown).
Analysis of the frequency of single AAs in the duplicated region
revealed that arginine 595 was the most frequently duplicated
single AA in 77%, followed by Y597 in 74%, and F594 and E596 in
73% of all patients (Figure 1).
Next, we analyzed the frequency of AA combinations, ranging
in length from 1 to 30 AAs within the duplicated region. As shown
in Figure 2A, the single R595 is subsequently followed by the
combination of amino acids EY (AA596-597) and REY (AA595-
597) in 70% of all patients.
These findings point to a commonly duplicated motif that
centers around R595 within the Y-rich stretch from AAs 591 to 599
(YVDFREYEY). We hypothesized that this region might play an
important role for the transforming activity of FLT3-ITDs. To
confirm this hypothesis, we analyzed the patients that carried the
shortest ITDs. Figure 2B shows the duplicated sequences of 25
Table 1. Clinical and laboratory data of the patients analyzed
in this study
N
No. of patients 284
Age
Range 18-89
Median 60.5
Sex
Female 163
Male 121
FAB class
AUL 2
Biphenotypic 3
ALL 4
AML M0 6
AML M1 63
AML M2 49
AML M3 28
AML M4 39
AML M5 21
AML M6 4
MDS 3
AML with unknown FAB 52
Patients without clinical data 10
WBC count
Median 50000
Range 12000-67500
Cytogenetic abnormality
Favorable 29
Intermediate 185
Adverse 11
Unknown 49
AUL indicates acute undifferentiated leukemia, AML, acute myeloid leukemia;
MDS, myelodysplastic syndrome; and WBC, white blood cell.
Favorable, intermediate, and unfavorable cytogenetic abnormality has been
defined according to published data.65
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patients ranging in length from 2 to 8 AAs. The patient with the
shortest duplication (2 AAs) showed insertion of R595 and E596.
All but 4 patients (21/25  84%) had duplications of R595.
Moreover, all patients had duplications of at least one amino acid of
the protein stretch REYEY (AAs 595 to 599).
Taken together, our data show that a common duplicated AA
stretch can be defined in patients with FLT3-ITDs. This region
includes R595, which is duplicated in 77% of all patients and
supports the hypothesis that this residue might play an important
role for the transforming potential of FLT3-ITDs.
Insertion of a single arginine between AAs 595 and 596 in
FLT3-WT confers IL-3–independent growth to Ba/F3 cells along
with activation of STAT5
The acquisition of FLT3-ITD mutations in the FLT3 gene was
shown to induce constitutive activation of the receptor and
ligand-independent cell growth in different cell lines.5,16,32,46 To
validate our hypothesis that duplication of R595 plays an important
role for the transforming activity of the receptor, we introduced an
arginine in the FLT3-WT cDNA between positions 595 and 596
(FLT3-ins595R). The second and third most frequently duplicated
AA combinations E596/Y597 (FLT3-ins597EY) and R595/E596/
Y597 (FLT3-ins597REY), and also the shortest duplication found
in patients (ie, AA combination R595/E596 [FLT3-ins597RE])
were generated by in vitro mutagenesis (Figure 3A). Furthermore,
we analyzed if tandem duplication of AAs outside the region of
AA592-599 can confer factor-independent growth to cells. Hence,
we generated 2 different hypothetical ITDs that have duplications
outside the AAs 592-595 stretch (FLT3-WT-ins591YFY and FLT3-
WT-ins602KWE in FLT3-WT) using in vitro mutagenesis (Figure 3A).
We stably transduced the pro-B-cell line Ba/F3 with the
FLT3-WT-ins595R/ins596RE/ins597EY/ins597REY/ins591YFY/
ins602KWE constructs. In addition, Ba/F3 cells expressing
FLT3-WT and FLT3-ITD-W51 were generated. Expression of all
FLT3 constructs was confirmed by CD135 antibody staining and
fluorescence-activated cell sorting (FACS) analysis as well as
Western blotting (data not shown).
Overexpression of the mutant FLT3-ins595R, but not FLT3-
WT, induced IL-3–independent growth in Ba/F3 cells (Figure 3B).
In detail, the growth rate of FLT3-ins595R was 40% compared to
cells expressing the FLT3-ITD-W51 construct, which served as a
positive control. Similar results were obtained for cells expressing
FLT3-ins597RE (50.7%) and FLT3-ins597REY (58.9%), but with
slightly increased growth rate. When expressed in Ba/F3 cells, the
FLT3-insEY construct induced a 15% growth rate compared to
FLT3-ITD-W51 (Figure 3B). The cells expressing the constructs
FLT3-WT-ins591YFY and FLT3-WT-ins602KWE also showed
factor-independent growth of 28% and 24%, respectively, when
compared to FLT3-ITD-W51 (Figure 3B), but again the transform-
ing potential was weaker when compared to the cells expressing
FLT3-ins595R, FLT3-ins596RE, and FLT3-ins597REY. To analyze
whether the autonomous growth of these mutants might be further
stimulated by exogenous ligand, all these mutant cell lines were
grown in the presence of 60 ng FLT3 ligand (FL)/mL, and viable
cells were counted after 72 hours. All mutants showed a growth rate
which was 1.3 to 3 times higher, than that of FLT3-WT cells grown
under identical conditions (Figure 3B). These data clearly indicate
that the duplication of R595 is sufficient to activate the transform-
ing potential of FLT3. Introduction of an ITD outside the AA
stretch 591 to 595 resulted in weaker transforming potential
compared to constructs carrying R595 duplication
STAT5 is the downstream target of the constitutively activated
FLT3 receptor probably responsible for most of the transforming
potential of the FLT3 receptor in vitro and in vivo.46-48 To
investigate the activation of the STAT5 signaling pathway, we
prepared crude cell lysates of serum-starved Ba/F3 cells transduced
with either vector control (MIY) or FLT3WT, FLT3-ITD-W51,
Figure 2. Duplications locate in the motif YVDFREYEY and
include R595 in 77% of patients. (A) Most frequent AA combina-
tions within the duplicated region, sorted by length from 1 to 30
AAs. (B) Panel showing the duplicated sequences of 25 patients
ranging from 2 to 8 AAs.
Figure 1. Analysis of the AA composition in the duplicated region in FLT3-ITDs.
Frequency of single AAs by position in the duplicated region is provided. For each
position, the most frequent single AA was selected.
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FLT3-ins595R, FLT3-ins597EY, FLT3-ins597RE, and FLT3-
ins597REY. Lysates were analyzed by immunoblotting with a
specific antibody against phospho-STAT5. We could clearly demon-
strate that the expression of FLT3-ins595R, FLT3-ins597EY,
FLT3-ins597RE, and FLT3-ins597REY led to increased phos-
phorylation of tyrosine at position 694 of STAT5 compared to
FLT3-WT in accordance with the proliferation data; the FLT3-
ins597EY mutant showed a significantly weaker STAT5 activa-
tion (Figure 3C-D)
Deletions or substitutions of arginine 595 with alanine or
glutamic acid in the duplicated region of FLT3-ITD reduce the
proliferation rate of FLT3-ITD–transformed cells
Having shown that duplication of R595 can activate the transform-
ing activity of FLT3, we asked whether R595 is necessary for the
oncogenic potential of FLT3-ITD mutants.
For this purpose, we substituted the positively charged dupli-
cated AA arginine (R602) with the neutral AA alanine (FLT3-W51-
R602A) and also with the negatively charged AA glutamic acid
(FLT3-W51-R602E) (Figure 4A). Furthermore, we generated a
deletion mutant of duplicated R595 (FLT3-W51R602) (Figure
4A) and the deletion of neighboring AA glutamic acid (FLT3-
W51E603) (Figure 4A). Ba/F3 cells were stably transduced with
these different FLT3-ITD-W51 mutants and with FLT3-WT and
FLT3-ITD-W51 as controls.
In proliferation assays, FLT3-W51R602–, FLT3-W51-R602E–,
and FLT3-W51-R602A–expressing cells showed a growth reduc-
tion of approximately 55% to 70% when compared to FLT3-W51
cells (Figure 4B), with the deletion mutant showing the maximum
growth reduction of 70%. Next, we generated a deletion mutant of
duplicated R595 (FLT3-NPOS-623R) in a structurally different
FLT3-ITD construct, FLT3-ITD-NPOS, that contains a 28-AA–
duplicated sequence (CSSDNEYFYDFREYEYDLKWEFPRENL)
inserted between AAs 611/612 of FLT3-WT (Figure 4A). Expres-
sion of the deletion mutant (FLT3-NPOS-623R) showed a similar
phenotype compared to FLT3-W51R602 with a reduction of
approximately 70% of its proliferative capacity when compared to
the FLT3-ITD-NPOS construct (Figure 4C). Deletion mutant of
neighboring AA (FLT3-W51E603) did not result in a significant
growth reduction (Figure 4B).
Substitution of duplicated R595 with lysine did not alter the
proliferation rate of the FLT3-ITD mutants
Having shown that the positively charged arginine plays an
important role in the transforming potential of FLT3-ITDs, we
asked if the duplicated arginine can be replaced with another
positively charged amino acid. Hence, we substituted the dupli-
cated arginine with the positively charged AA lysine (FLT3-W51-
R602K) (Figure 4A). Overexpression of FLT3-W51-R602K in
Ba/F3 cells induced factor-independent growth and did not show
any reduction of the transforming potential when compared to
FLT3-ITD-W51 (Figure 4D). These data clearly show that the
positive charge of the AA (arginine or lysine) plays a crucial role in
the transforming potential of FLT3-ITDs.
FLT3-ITD–duplicated R595 substitution/deletion mutants show
a reduced capacity to activate STAT5 compared to FLT3-ITDs
To investigate the activation of the STAT5 signaling pathway, we
prepared crude cell lysates of serum-starved Ba/F3 cells, trans-
duced with either vector control (MIY) or FLT3-WT, FLT3-ITD-
W51, FLT3-ITD-NPOS, FLT3-W51-R602A, FLT3-W51-R602E,
FLT3-W51-R602K, FLT3-W51-R602, FLT3-W51-E603, and
FLT3-NPOS-R623. All the mutants FLT3-W51-R602A, FLT3-
W51-R602E, FLT3-W51-R602, and FLT3-NPOS623R in Ba/F3
cells reduced the STAT5 activation compared to nonmanipulated
FLT3-ITD constructs (Figure 5). STAT5 activation of FLT3-W51-
R602K was similar to the FLT3-ITDs. Thus, the activation of the
most important signaling pathway downstream of FLT3, STAT5,
showed reduced phosphorylation in FLT3-W51-R602A, FLT3-W51-
R602E, FLT3-W51602R, and FLT3-NPOS623R, but not in
FLT3-W51-R602K–expressing cells, which correlates with IL-3–
independent growth.
Figure 3. Duplication of single arginine 595 in FLT3 induces
IL-3–independent growth in Ba/F3 cells. (A) Localization of 6
insertion mutants of FLT3 generated by duplication of 1 to 3 AAs
of the stretch between 3 AA regions: 595 to 597, 589 to 591, and
602 to 604. (B) Ba/F3 cells stably transduced with FLT3-WT,
FLT3-ITD-W51, FLT3-ins595R, FLT3-ins596RE, FLT3-ins597EY,
FLT3-ins597REY, FLT3-WT-ins591YFY, FLT3-WT-ins602KWE, or
mock-transduced cells were seeded at a density of 4  104
cells/mL in the absence or presence of IL-3 or FL (60 ng/mL).
Viable cells were counted after 72 hours by trypan blue exclusion.
The growth of cells with IL-3 was defined as 100% (control).
Standard error of the mean calculated from 3 independent
experiments is shown. (C) Western blot showing the autoactiva-
tion of STAT5 in the mutants FLT3-ins595R, FLT3-ins597EY,
FLT3-ins597REY, and FLT3-ITD-W51 when compared to FLT3-WT
in the unstimulated cells. FLT3-WT-ins595R, FLT3-WT-ins597EY,
FLT3-WT-ins597REY, FLT3-WT-ins596RE, FLT3-ITD-W51, FLT3-
WT, or mock-transduced cell lines were starved for 24 hours in the
presence of 0.3% FBS and stimulated with 60 ng FL/mL for 5
minutes. Crude cell lysates were separated by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and blot-
ted on a nitrocellulose membrane. Blots were then incubated with
anti–phospho-STAT5 antibody, stripped, and reblotted with anti-
STAT5 antibody. (D) Densitometric analysis of the Western image
in panel C was used to quantify the ratio of phospho-STAT5 to
total STAT5.
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Deletion of wild-type R595 reduces the transforming potential
and STAT5 activation of FLT3-ITD mutants
Since the duplicated arginine plays an important role in the
transforming potential of the FLT3-ITDs, we asked whether
wild-type R595 also has a critical role in the transforming capacity
of FLT3-ITDs. We therefore created a deletion mutant of R595 in
FLT3-ITD-W51 (FLT3-W51-R595) (Figure 6A).
Overexpression of the wild-type arginine deletion mutant
FLT3-W51-R595 reduced the IL-3–independent growth by 64%
when compared to FLT3-ITD-W51 (Figure 6B). These prolifera-
tion data were supported by the measurement of STAT5 activation
(Figure 6C). STAT5 activation was significantly lower in the cells
expressing FLT3-W51-R595, when compared to FLT3-ITD-
W51. These data suggest that not only the duplicated R595 but also
the wild-type R595 plays an important role in the transforming
potential and STAT5 activation of FLT3-ITD-W51.
Deletion of R595 in FLT3-WT nearly abrogates the growth of
cells upon FL stimulation
As wild-type R595 had a significant effect on the transforming
properties of FLT3-ITDs, we analyzed the role of the wild-type
arginine 595 in the signaling properties of the FLT3-WT receptor.
Figure 4. The positive charge of duplicated arginine 595 is
critical for transforming potential of FLT3-ITDs. (A) Shows 3
different substitution and 2 deletion mutants of duplicated R595
generated in 2 different FLT3-ITDs (W51 and NPOS). The
deletion mutant of duplicated E596 in FLT3-ITD-W51 is also
shown. (B) Ba/F3 cells stably transduced with FLT3-WT, FLT3-ITD-
W51, FLT3-W51-R602A, FLT3-W51-R602E, FLT3-W51-R602,
FLT3-W51-E603, or mock-transduced cells were seeded at a
density of 4  104 cells/mL in the absence or presence of IL-3.
Viable cells were counted after 72 hours. The growth of cells with
IL-3 was defined as 100% (control). Standard error of the mean
calculated from 3 independent experiments is indicated. (C-D)
The mutants FLT3-NPOSR623 and FLT3-W51-R602K were
expressed in Ba/F3 cells and analyzed as described in panel B.
Figure 5. The constitutive STAT5 activation is reduced in substitution/deletion
mutants of duplicated R595. FLT3-WT–, FLT3-ITD-W51–, FLT3-ITD-NPOS–,
FLT3-W51-R602A–, FLT3-W51-R602E–, FLT3-W51-R602K–, FLT3-W51-R602–,
FLT3-W51-E603–, and FLT3-NPOS-R623–expressing cells were starved for 24
hours in the presence of 0.3% FBS. Blots were incubated with anti–phospho-STAT5
antibody, stripped, and reblotted with anti-STAT5 antibody.
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Hence, we created a deletion mutant of R595 in FLT3-WT
(FLT3-WT-R595) (Figure 7A) and expressed it in Ba/F3 cells.
Overexpression of FLT3-WT-R595 did not show any IL-3–
independent growth, but cell proliferation was almost abrogated in
the presence of FL, when compared to FLT3-WT (Figure 7B). In
detail there was a reduction of approximately 90% in the prolifera-
tion of cells expressing FLT3-WT-R595 after stimulation with
FL, when compared to cells expressing FLT3-WT (taken as 100%)
To check the signaling pathway of STAT5, we prepared crude
cell lysates of serum-starved Ba/F3 cells transduced with MIG,
FLT3-WT, and FLT3-WT-R595 and FLT3-ITD-W51 acting as
positive control. Lysates were analyzed by immunoblotting with a
specific antibody against phospho-STAT5. We detected very slight
STAT5 activation in the FLT3-WT-R595 in the presence of FL,
when compared to FLT3-WT–expressing cells (Figure 7C).
The arginine substitution/deletion mutants of FLT3-ITDs are
sensitive to the FLT3 PTK inhibitor PKC12
PKC412 (Novartis Pharma), an inhibitor initially discovered as an
inhibitor of protein kinase C, was found to block the phosphoryla-
tion and activity of FLT3-WT and mutant FLT3 receptors.49,50 The
inhibitory activity of PKC412 against the arginine mutants of
FLT3-ITDs was analyzed by treating the FLT3-W51-R602A–,
FLT3-W51-R602E–, FLT3-W51602R–, and FLT3-NPOS623R–
expressing cells with different concentrations of PKC412 ranging
from 1 to 100 nM. PKC412 showed a strong growth inhibitory
effect on FLT3-W51R602A, FLT3-W51-R602E, FLT3-W51-
R602K, FLT3-W51602R, and FLT3-NPOS623R receptors ex-
pressing cells in the absence but not in the presence of IL-3. The
IC50 of PKC412 was significantly lower in arginine substitution/
deletion mutants (0.5-1 nM) compared to FLT3-ITD mutants (4
nM) (Table 2).
Discussion
FLT3-ITDs are found in 20% to 25% of AML patients and are
associated with an adverse prognosis. Recently, 2 different studies
have reported conflicting results, stating the importance of the
length of the duplication for the prognostic significance of the
Figure 6. Deletion of wild-type R595 in FLT3-ITD-W51 results in
reduced transforming potential and STAT5 activation in Ba/F3 cells.
(A) Schematic representation of wild-type R595 (FLT3-W51-R595)
deletion mutant in the FLT3-ITD-W51 construct. (B) Ba/F3 cells express-
ing the FLT3-WT, FLT3-W51-R595, FLT3-ITD-W51, and mock-trans-
duced cells were seeded at a density of 4  104 cells/mL in the absence or
presence of IL-3. Viable cells were counted after 72 hours by trypan blue
exclusion. The growth of cells with IL-3 was defined as 100% (control). The
standard error of the mean calculated from 3 independent experiments is
indicated. (C) Western blot image showing the activation of STAT5 in cells
expressing FLT3-W51-R595 and FLT3-ITD-W51, when compared to
FLT3-WT or mock-transduced cells. Cells were starved in the presence of
0.3% FBS for 24 hours. Blots were incubated with anti–phospho-STAT5
antibody, stripped, and reblotted with anti-STAT5 antibody.
Figure 7. Deletion of wild-type R595 in FLT3-WT abrogates
the ligand-dependent activation of FLT3-WT in Ba/F3 cells.
(A) Schematic representation of wild-type R595 (FLT3-WT-
R595) deletion mutant in the FLT3-WT construct. (B) Ba/F3 cells
expressing the FLT3-WT, FLT3-WT-R595, FLT3-ITD-W51, and
mock-transduced cells were seeded at a density of 4  104
cells/mL in the absence or presence of IL-3 and FL (60 ng/ml).
Viable cells were counted after 72 hours by trypan blue exclusion.
The growth of cells with IL-3 was defined as 100% (control). The
standard error of the mean calculated from 3 independent
experiments is indicated. (C) Western blot image showing the
abrogation of activation of STAT5 in cells expressing FLT3-WT-
R595, when compared to FLT3-ITD-W51 and FLT3-WT, upon
stimulation of FL (60 ng/mL). Cells were starved in the presence
of 0.3% FBS for 24 hours. Blots were incubated with anti–phospho-
STAT5 antibody, stripped, and reblotted with anti-STAT5 antibody.
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mutation. One study showed that longer duplications are associated
with an unfavorable prognosis in patients with AML, whereas
another study found the opposite.51,52 Given the substantial struc-
tural heterogeneity of FLT3-ITD mutations, no common motif has
been identified so far that is duplicated in all patients. We
sequenced the JM region of FLT3 in 284 patients with acute
leukemias carrying internal tandem duplications in order to look
for a common signature in these ITDs.
Our results confirm previous data showing that internal tandem
duplications are heterogeneous with respect to length. The analysis
of single residues within the duplicated region showed that R595
was the single most frequently duplicated AA in 77% of the
patients, followed by Y597 in 73%, and F594 and E596 in 71% of
all patients. A detailed statistical analysis of AA combinations from
1 to 30 AAs in the duplicated regions showed that, although there is
no central motif common in all patients, the site of insertion
(mutational hotspot) is frequently located in or around the Y-rich
stretch region from AAs 591 to 599 (YVDFREYEY) of FLT3.
R595 is duplicated in 77% of the patients followed by a combina-
tion of EY (E596 and Y597) in 70% of patients. In vitro studies
showed that duplication of R595 in FLT3 is able to confer
factor-independent growth to Ba/F3 cells and led to activation of
STAT5. Substitution of the duplicated R595 with alanine
(R602A) or glutamic acid (R602E) in a representative FLT3-ITD-
W51 construct showed a significant reduction in the transform-
ing potential of FLT3-ITD-W51. In contrast, substitution of the
duplicated R595 with the positively charged AA (R602K) did
not alter the transforming potential of cells compared to
FLT3-ITD-W51 construct.
Statistical analysis of our data showed that R595 is the most
frequently duplicated single AA. Moreover, the analysis of patients
with the shortest duplications showed that R595 was duplicated in
84% of these patients. Of interest, the shortest duplication found in
our cohort was R595/E596 duplication. This prompted us to check
if a single R595 duplication was sufficient to confer factor-
independent growth to Ba/F3 cells. In vitro, duplication of a single
AA, R595 (FLT3-ins595R), was sufficient to activate the transform-
ing potential of FLT3. The weak transforming phenotype of
FLT3-ins595R could be attributed to a slight disturbance in the
autoinhibitory conformation of the JM region caused by a single
amino acid insertion. Similar results were reported by our group on
point mutations in the JM region found in AML patients that have a
weak transforming potential, when compared to FLT3-ITDs.31
Addition of AAs next to arginine (FLT3-ins596RE, FLT3-
ins597REY) increased the transforming potential but only slightly
when compared to FLT3-ins595R. Moreover, FLT3-ITD mutant
lacking the R595 duplication (ie, FLT3-ins595EY or FLT3-WT-
ins591YFY/FLT3-WT-ins602KWE, which carry duplications out-
side AAs 592-599 stretch) showed a weaker transforming potential
when compared to FLT3-ins595R (40.9%), FLT3-ins596RE
(50.7%), FLT3-ins597REY (58.9%), and FLT3-ITD-W51 (92%).
These data clearly show that the duplicated R595 plays an
important role for the higher transforming potential of FLT3-ITDs.
Ba/F3 cells expressing FLT3-ins595R, FLT3-ins597EY, FLT3-
ins596RE, FLT3-ins597REY, FLT3-WT-ins591YFY, and FLT3-WT-
ins602KWE showed hyperresponsiveness to FLT3 ligand, with a
1.3 to 3 times higher proliferation rate compared to FLT3-WT cells.
This experimental setting probably reflects the in vivo situation, as
it has been found that FL is coexpressed in AML blasts.54
FLT3-ITDs mutants are strong activators of STAT5,47,55 and
STAT5 has been shown to be activated in blasts of 20% to 80% of
patients with AML.56-59 Previous studies have also shown that
STAT5 regulates the expression of early cytokine genes, such as
PIM-1,60 which are responsible for cell survival and growth, and
leads to tumor development and progression.61 In accordance with
the proliferation data, all the mutants FLT3-ins595R, FLT3-
ins596RE, FLT3-ins597REY, and FLT3-ins597EY showed activa-
tion of STAT5, but to a lesser degree compared to the FLT3-ITD-
W51 mutant.
Determination of the crystal structure of FLT3-WT has indi-
cated that the JM can be divided into 3 parts.33 The JM binding
motif (JM-B) acts as the autoinhibitory domain, by preventing the
rotation of the N lobe toward the C lobe of the tyrosine kinase
domain (TKD) to generate the activated kinase fold, whereas the
JM switch motif (JM-S) that lies next to JM-B provides a rigid and
properly oriented scaffold for the interposition of tyrosines 589 and
591 between the JM-S and the C lobe of the kinase. FLT3-ITDs are
frequently found in the JM zipper region (JM-Z) that aligns and
maintains the JM-S in the proper orientation during and after the
transition between activated and inactive states of FLT3. It is hard
to predict the mechanisms by which these FLT3-ITDs change the
conformation of the FLT3 protein, but it is hypothesized that the
duplications offset the position of the JM-S in the FLT3 structure.
This results in disturbing or preventing the optimal orientation of
JM-S as it tries to position the JM-B in its binding site. Since
FLT3-ins597EY showed a transforming potential 2 to 4 times lower
than FLT3-ins595R, FLT3-ins596RE, and FLT3-ins597REY, we
hypothesized that the positive charge of R595 might be involved in
forming crucial interactions with other AAs. These new interac-
tions might not only disrupt the autoinhibitory loop formed by
JM-B, but also promote higher tyrosine phosphorylation by
rendering the JM domain more accessible for autophosphorylation.
To analyze whether the positive charge of the duplicated R595
has any role for the oncogenic potential of FLT3-ITDs, we
generated substitution mutants of the duplicated R595 with an
aliphatic AA, alanine (FLT3-W51-R602A), and a negatively charged
AA, glutamic acid (FLT3-W51-R602E), as well as a deletion
mutant of the duplicated R595 (FLT3-W51-R602) in the strongly
transforming FLT3-ITD-W51. All mutants showed factor-indepen-
dent growth in Ba/F3 cells, but the transforming potential of these
mutants was reduced by 55% to 70% compared to FLT3-ITD-W51.
The same degree of reduction was seen after deletion of the
duplicated R595 in a different FLT3-ITD (FLT3-NPOS-R623)
construct. Of interest, there was no effect on the transforming
potential when the duplicated R595 was replaced by another
positively charged AA (eg, lysine; FLT3-W51-R602K). Deletion of
the AA adjacent to arginine in FLT3-ITD-W51 (FLT3-W51E603)
Table 2. IC50 of PKC412 values in different FLT3-ITD arginine mutants
Mutant IC50, nM
FLT3-ITD(W51/NPOS) 4.0
FLT3-W51-R602A 0.9
FLT3-W51-R602E 0.8
FLT3-W51-R602K 4.0
FLT3-W51-R602 0.6
FLT3-NPOS-R623 0.7
Ba/F3 cells expressing FLT3-WT, FLT3-ITD-W51, FLT3-ITD-NPOS, FLT3-W51-
R602A, FLT3-W51-R602E, FLT3-W51-R602K, FLT3-W51-R602, and FLT3-NPOS-
R623 seeded at a density of 4  104 cells/mL in the absence or presence of different
concentrations of PKC412 (0 to 100 nM) and counted after 72 hours. All cell lines
were also cultured in the presence of IL-3 and 100 nM PKC412 to confirm nontoxicity
of PKC412 to Ba/F3 cells. The IC50 was calculated from 3 independent experiments
(IC50 is defined as the concentration of inhibitor required to induce a growth reduction
of 50% compared to the cells grown in the absence of inhibitor).
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did not significantly reduce the transforming potential of FLT3-ITD-
W51, confirming that the positive charge of the duplicated R595
plays an important role in transforming potential of FLT3-ITDs.
This hypothesis is further supported by the finding that deletion of
WT-R595 in FLT3-ITD-W51 (FLT3-W51R595) reduces the
growth rate of Ba/F3 cells by 64% compared to the FLT3-ITD-W51
construct. All deletion and substitution mutants of wild-type and
duplicated R595 in FLT3-ITDs (W51 and NPOS) showed a
reduction in the activation of STAT5 except for the FLT3-W51-
R602K, suggesting that the positive charge of wild-type and
duplicated R595 has an essential role in the activation of STAT5.
As the positive charge of both duplicated and wild-type R595
was critical on the transforming potential of FLT3-ITDs, we
wanted to check for the effect of R595 in the ligand-dependent
activation of FLT3-WT. Deletion of R595 in FLT3-WT (FLT3-WT-
R595) nearly abrogated the growth of cells expressing FLT3-WT-
R595 upon stimulation with FL when compared to cells express-
ing FLT3-WT. This was further confirmed by the STAT5 signaling
where the cells expressing the FLT3-WT-R595 showed very
weak activation of STAT5 when compared to FLT3-WT. These data
clearly show that R595 regulates the mitogenic activity of FLT3-WT
and its constitutively activated receptor mutants.
The importance of FLT3 for the survival and proliferation of
AML blasts, and its mutation and overexpression in a large cohort
of AML patients, has led to development of selective FLT3 protein
tyrosine kinase inhibitors such as PKC412 and CEP-701. These
inhibitors block the FLT3 kinase activity, thereby inducing apopto-
sis in FLT3-expressing cell lines, and cause cytotoxicity in primary
ALL and AML blasts.49,62-64 PKC412, which was originally devel-
oped as an inhibitor of PKC, has also been found to inhibit FLT3
phosphorylation in vitro and in vivo.49,50,62 We tested the effect of
PKC412 on the described substitution and deletion mutants of
duplicated R595 in FLT3-ITD compared to nonmanipulated FLT3-
ITD constructs as a control. The IC50 of PKC412 in FLT3-W51-
R602A–, FLT3-W51-R602E–, FLT3-W51-R602–, and FLT3-
NPOS-R623–expressing Ba/F3 cells was approximately 5 times
lower in Ba/F3 cells expressing nonmanipulated FLT3-ITDs. In
contrast, there was no difference in the IC50 of PKC412 for
FLT3-W51-R602K–expressing Ba/F3 cells compared to FLT3-ITD-
W51 cells. The high sensitivity of FLT3-W51-R602A, FLT3-W51-
R602E, FLT3-W51-R602, and FLT3-NPOS-R623 toward
PKC412 might be due to their weak transforming potential as seen
in our study for point mutants in the JM region of FLT3.31
Our results clearly show that R595 is duplicated in 77% of the
patients with FLT3-ITDs and plays a critical role for the transform-
ing potential of FLT3-ITD mutants and ligand-dependent activa-
tion of FLT3-WT.
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NEOPLASIA
Point mutations in the juxtamembrane domain of FLT3 define a new class of
activating mutations in AML
Carola Reindl, Ksenia Bagrintseva, Sridhar Vempati, Susanne Schnittger, Joachim W. Ellwart, Katja Wenig, Karl-Peter Hopfner,
Wolfgang Hiddemann, and Karsten Spiekermann
In acute myeloid leukemia (AML), two
clusters of activating mutations are known
in the FMS-like tyrosine kinase-3 (FLT3)
gene: FLT3-internal tandem duplications
(FLT3-ITDs) in the juxtamembrane (JM)
domain in 20% to 25% of patients, and
FLT3 point mutations in the tyrosine-
kinase domain (FLT3-TKD) in 7% to 10%
of patients, respectively. Here, we have
characterized a new class of activating
point mutations (PMs) that cluster in a
16–amino acid stretch of the juxtamem-
brane domain of FLT3 (FLT3-JM-PMs).
Expression of 4 FLT3-JM-PMs in interleu-
kin-3 (IL-3)–dependent Ba/F3 cells led to
factor-independent growth, hyperrespon-
siveness to FLT3 ligand, and resistance
to apoptotic cell death. FLT3-JM-PM re-
ceptors were autophosphorylated and
showed a higher constitutive dimeriza-
tion rate compared with the FLT3–wild-
type (WT) receptor. As a molecular mecha-
nism, we could show activation of STAT5
and up-regulation of Bcl-x(L) by all FLT3-
JM-PMs. The FLT3 inhibitor PKC412 abro-
gated the factor-independent growth of
FLT3-JM-PM–expressing cells. Compared
with FLT3-ITD and FLT3-TKD mutants, the
FLT3-JM-PMs showed a weaker trans-
forming potential related to lower auto-
phosphorylation of the receptor and its
downstream target STAT5.
Mapping of the FLT3-JM-PMs on the crys-
tal structure of FLT3 showed that these
mutations reduce the stability of the auto-
inhibitory JM domain, and provides a struc-
tural basis for the transforming capacity of
this new class of gain-of-function mutations
of FLT3. (Blood. 2006;107:3700-3707)
© 2006 by The American Society of Hematology
Introduction
FMS-like tyrosine kinase-3 (FLT3) has been shown to be mutated
in about one-third of patients with acute myeloid leukemia (AML),
representing one of the most frequently occurring mutations in this
disease.1,2 Until now, two distinct clusters of activating mutations
are known: FLT3-internal tandem duplications (FLT3-ITDs) in the
juxtamembrane (JM) domain in 20% to 25% of patients, and point
mutations (PMs) in the tyrosine-kinase domain (FLT3-TKD) in 7%
to 10% of patients.3-9
Recently, the crystal structure of the autoinhibited form of FLT3
was resolved.10 The structure conforms to the prototypical
conformation common to other inactive kinases that have a
“closed” activation loop, but the remarkable feature is the
complete JM domain serving as a critical autoinhibitory loop
and interacting with all key features of FLT3. This domain can
be divided into three distinct parts: the JM binding motif
(JM-B), JM switch motif (JM-S), and the zipper or linker
peptide segment (JM-Z). According to that model, the JM-B
region is nearly buried in the FLT3 structure. It serves as an
autoinhibitory domain, which in an inactive state prevents the N
lobe from rotating toward the C lobe of the tyrosine kinase
domain (TKD) to generate the activated kinase fold.
The cytoplasmatic juxtamembrane domain is highly conserved
between different members of the class III receptor tyrosine kinase
(RTK) family. A variety of tumors in animals and humans have
been described that harbor activating mutations in the JM do-
main.11-14 The most frequently occurring activating mutations in
AML, FLT3-ITDs, occur primarily in the JM-Z domain. They
represent a heterogenous group of mutations, where a fragment of
the JM domain, varying in length from 2 to 204 nucleotides (nt), is
duplicated and inserted in a direct head-to-tail orientation always
maintaining the reading frame.
Recently, we discovered a novel missense point mutation in the
JM domain of FLT3 in the AML cell lines Mono-Mac (MM)–1 and
MM-6, changing valine with alanine at position 592.15 By perform-
ing a LightCycler (Roche, Mannheim, Germany) mutational screen-
ing of FLT3 in 785 AML patient samples, we were able to identify
two other point mutations: F594L in two AML patients and Y591C
in 1 AML patient. In addition, Stirewalt et al16 found additional
point mutations in the JM domain of FLT3 (V579A and
F590GY591D) in AML patients by using single-stranded conforma-
tional polymorphism analyses (polymerase chain reaction
[PCR]/SSCPs).
Here, we have studied the functional significance of this new
class of activating mutations in patients with AML: PMs that
cluster in a 16-aa stretch of the JM domain (FLT3-JM-PMs).
We could clearly demonstrate that FLT3 receptors harboring
one of these JM point mutations, when expressed in Ba/F3 cells,
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induced interleukin-3 (IL-3)–independent growth, increased resis-
tance to apoptosis via up-regulation of Bcl-x(L) and constitutive
activation of the receptor and STAT5. Treatment with a specific
FLT3 phospho-tyrosine-kinase (PTK) inhibitor, PKC412, was able
to block IL-3–independent proliferation and resulted in reduced
phosphorylation of STAT5. These data clearly define a third class
of activating mutations in AML. Patients with AML harboring
these mutations may respond to small-molecule FLT3 inhibitors
like PKC412.
Materials and methods
Patient samples
All samples of bone marrow or peripheral blood (with at least 70%
circulating blast cells), were obtained at diagnosis and were sent to the
leukemia diagnostics laboratory, Munich, Germany. All patients gave
informed consent before entering the study. The study design adhered to the
principles of the Helsinki Declaration and was approved by the ethics
committees of the participating institutions. A total of 785 unselected AML
samples were analyzed.
Screening method for mutations in the juxtamembrane
domain of FLT3
Mononucleated cells were isolated by standard Ficoll-Hypaque density
gradient centrifugation. Nucleic acid isolation and cDNA synthesis was
performed as described before.5 Screening for FLT3-V592A mutations was
performed using a melting curve–based LightCycler assay with forward
primer FLT3JM-F: CAATTTAGGTATGAAAGCCAG, reverse primer
FLT3JM-R: TGATCCTAGTACCTT; and hybridization probes FLT3JM-S
(sensor) TTCATATTCTCTGAAATCAACGTAGAAGT-FL, and FLT3JM-A
(anchor) LC-Red640-TCATTATCTGAGGAGCCGGTCACCT-P. The PCR
reaction was carried out in a 20-L reaction volume with each 0.5 M
forward and reverse primer, 0.75 M Hyb-Probes (Metabion, Martinsreid,
Germany) 4 mM MgCl2, and 2 L LightCycler-FastStart DNA Master
Hyb-Probes (Roche Diagnostics, Mannheim, Germany). LightCycler data
were analyzed using LightCycler 3.0 software (Roche Diagnostics) and the
second derivative maximum method. Each 20-L reaction contained 2 L
cDNA, an equivalent of about 3000 cells. Amplification was performed
with 40 cycles using 50°C annealing temperature. Final melting curve
analysis was started at 35°C up to 85°C with slope of 0.2°C/sec and
continuous detection with channel F2/F1.
Reagents and cell lines
Low-passage murine Ba/F3 cells were obtained from the DSMZ (Deutsche
Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Ger-
many) and were maintained in RPMI-1640 medium with 10% fetal bovine
serum (FBS) and 10% WEHI-conditioned medium as a source of murine
IL-3 when indicated. PKC412 was kindly provided by Novartis Pharma
(Basel, Switzerland).
Cell proliferation of Ba/F3 cells
Cells were seeded at a density of 4  104/mL in the presence or absence of
IL-3 or FLT3 ligand (Promocell, Heidelberg, Germany) as indicated. Viable
cells were counted at indicated time periods in a standard hemacytometer
after staining with trypan blue. Figures show mean values and standard
deviations from three independent experiments.
Apoptosis analysis
Assessment of apoptotic cells was carried out by annexin V/7-aminoactino-
mycin D (7-AAD) staining as recommended by the manufacturer (annexin
V phycoerythrin [PE] apoptosis detection kit; Becton Dickinson, Heidel-
berg, Germany) using a FacsCalibur flow cytometer (Becton Dickinson,
San Jose, CA). Determination of the DNA content of cell nuclei was
performed by propidium iodide (PI) staining as described previously.17
Receptor dimerization experiments, immunoprecipitations, and
Western blot analyses
Experiments were performed as described previously.15,18 The following
antibodies were used: anti–phospho-STAT5-Tyr694, anti–phospho-AKT-
Ser473, anti-AKT, anti–phospho-p44/42 mitogen-activated protein (MAP)
kinase (Thr202/Tyr204), anti-p44/42 MAP kinase (all from New England
Biolabs, Frankfurt, Germany), anti-STAT5 (sc-835), anti–Bcl-x(L) (sc-
8392), anti-FLT3 (S18, sc-480), anti-PY (PY99) (all from Santa Cruz
Biotechnology, Heidelberg, Germany), and anti--actin (A-5441; Sigma,
Munich, Germany).
DNA constructs and vectors
The FLT3-ITD-W51 construct contained a 7-aa duplicated sequence
(REYEYDL) inserted between aa 601/602 of human FLT3-WT; the
FLT3-ITD-NPOS construct contained a 28-aa duplicated sequence (CSSD-
NEYFYVDFREYEYDLKWEFPRENL) inserted between aa 611/612 of
human FLT3-WT; and the FLT3-ITD-W78 construct contained a 22-aa
duplicated sequence (GLVQVTGSSDNEYFYVDFREYE) inserted be-
tween aa 598/599 of human FLT3-WT. The FLT3-ITD constructs were
kindly provided by Dr G. Gilliland (Howard Hughes Medical Institute and
Brigham and Women’s Hospital Harvard Institutes of Medicine, Harvard
Medical School, Boston, MA). All FLT3 constructs were subcloned in the
MSCV-IRES-EYFP retroviral expression vector (kindly provided by R. K.
Humphries, The Terry Fox Laboratory, University of British Columbia,
Vancouver, BC, Canada). The Bcl-x(L) construct was kindly provided by
S. J. Korsmeyer (Howard Hughes Medical Institute, Dana-Farber Cancer
Institute, Harvard Medical School, Boston, MA).
In vitro mutagenesis
The FLT3-JM point mutations (FLT3-V592A, FLT3-V579A, FLT3-F594L,
and FLT3-F590GY591D) and the FLT3-TKD point mutations (FLT3-
D835Y and FLT3-D835V) were introduced into the FLT3-WT construct
using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla,
CA) according to the manufacturers instructions. The correct sequence of
all constructs was confirmed by nucleotide sequencing.
Transient transfection of 293T cells
One day before transfection, 293T cells were seeded into 6-well plates at a
density of 3  105/mL. Transient transfections were then carried out using
the calcium-phosphate coprecipitation method with a total of 2 g plasmid
DNA per well. Eighteen hours after transfection, 2 mL fresh medium was
added, the cells were allowed to grow for another 30 hours, and the
retroviral supernatant was used for transduction of Ba/F3 cells.
Stable transduction of Ba/F3 cells
Ba/F3 cells (2  105) were seeded in 1 mL growth medium and subse-
quently transduced with 200 L retroviral supernatant in the presence of
polybrene (8 g/mL). The fluorescence-activated cell-sorting (FACS)–
Vantage system equipped with a Turbo-Sort device (Becton Dickinson,
San Jose, CA) was used to highly purify EGFP/EYFP-positive pool cells
48 hours after transduction. Expression of CD135 was performed as
described previously.15
Results
Detection of point mutations in the juxtamembrane domain of
FLT3 in patients with AML
By sequencing the complete cDNA of FLT3 in the AML cell lines
MM-1 and MM-6, we previously have found a new activating point
mutation substituting valine with alanine at position 592 in the
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functionally important JM domain of FLT3.15 These results encour-
aged us to perform a screen for point mutations at position 592 in
AML patient samples using a melting curve–based LightCycler
assay in a total of 785 samples. Two different point mutations were
identified in three patients: Y591C in a patient and F594L in two
patients. A recently published study by Stirewalt et al16 using
PCR/SSCP screened for mutations in FLT3 in exons 14 and 15 in
patients with AML. They detected two novel missense point
mutations in exon 14, V579A and F590GY591D, as well as V592A
in about 2% of patients with AML (Figure 1).16
These data show that a third class of mutations, point mutations
clustering in the JM domain of FLT3 (FLT3-JM-PMs), exist in
patients with AML.
So far, the biologic and clinical relevance of these findings have
not yet been investigated. We hypothesized that these mutations,
which are located in the functionally important JM region, may
play an important role in the pathogenesis of AML.
Point mutations in the JM domain of FLT3 confer
IL-3–independent growth to the pro–B-cell line Ba/F3
The acquisition of either ITD or TKD mutations in the FLT3 gene
was shown to induce constitutive activation of the receptor- and
ligand-independent cell growth in different cell lines.7,8,19-21 To
characterize the functional significance of point mutations in the
JM domain, we selected four of the described JM point mutations
and introduced them into the FLT3-WT cDNA (Figure 1). We
stably transduced the pro–B-cell line Ba/F3 with FLT3-V592A,
FLT3-V579A, FLT3-F594L, FLT3-F590GY591D, and FLT3-WT.
To directly compare these FLT3-JM-PM cell lines with known
activating mutations, we also stably transduced three different
FLT3-ITD constructs (FLT3-W51, FLT3-NPOS, and FLT3-W78)22
and two different FLT3-TKD constructs (FLT3-D835Y and FLT3-
D835V).22 Surface expression levels of FLT3 were confirmed by
CD135 antibody staining and FACS analysis (data not shown).
Overexpression of all FLT3-JM-PMs, but not FLT3-WT, in-
duced IL-3–independent growth in Ba/F3 cells (Figure 2A). In
detail, the growth rates of FLT3-V592A, FLT3-V579A, FLT3-
F594L, and FLT3-F590GY591D were 10%, 11%, 7%, and 18% of
the average growth rate of the 3 FLT3-ITD cell lines, respectively.
Also, the FLT3-TKD–expressing cells displayed significantly higher
growth rates than the FLT3-JM-PM–expressing cells. However,
among the 4 different FLT3-JM-PM–expressing cells there was no
consistent significant difference in terms of transforming activity.
To analyze whether the autonomous growth of FLT3-JM-PMs
might be further stimulated by exogenous ligand, all FLT3-JM-PM
cell lines were grown in the presence of 50 ng FLT3 ligand
(FL)/mL. Viable cells were counted after 72 hours by trypan blue
exclusion. The proliferation rates of FLT3-V592A, FLT3-V579A,
FLT3-F594L, and FLT3-F590GY591D were 412%, 286%, 197%,
and 248% compared with the growth of FLT3-WT cells grown
under identical conditions, respectively (Figure 2B).
Taken together, point mutations in the JM domain of FLT3 have
transforming potential in Ba/F3 cells, and these mutant receptors
confer a signficant proproliferative activity in response to FL.
FLT3-JM-PM–expressing Ba/F3 cell lines are resistant to
induction of apoptosis after IL-3 withdrawal
To gain a deeper insight into the phenotype of FLT3-JM-PM–
expressing Ba/F3 cells, we analyzed whether they exhibit antiapop-
totic activity. Two different assays were performed to identify cells
undergoing apoptotic cell death: staining of cells with annexin V
and 7-AAD after 48 hours, and staining of nuclei with propidium
iodide after 24 hours of growth factor withdrawal. FLT3-WT cells
rapidly underwent apoptosis after IL-3 withdrawal in contrast to
FLT3-ITD– and FLT3-TKD–expressing cells, which were pro-
tected from induction of apoptosis and served as a positive control
(Figure 3).
We could clearly demonstrate that the percentage of apoptotic
cells in FLT3-V592A–, FLT3-V579A–, FLT3-F594L–, and FLT3-
F590GY591D–expressing cell lines grown without IL-3 was
significantly lower compared with FLT3-WT after 48 and 24 hours
(Figure 3). In the absence of IL-3, the percentage of apoptotic cells
in cell lines expressing FLT3-WT was 26% and 80% after 24 and
Figure 1. Localization of point mutations in the JM domain of FLT3 (FLT3-JM-
PMs) found in patients with AML. The top panel shows the FLT3-WT juxtamem-
brane protein sequence from aa 573 to 600. Below are the four point mutants found in
our study (*) and the study of Stirewalt et al16 (†) in patients with AML.
Figure 2. FLT3-JM-PMs induce IL-3–independent
growth in Ba/F3 cells and hyperproliferation in re-
sponse to FL. (A) Ba/F3 cells stably transduced with
FLT3-WT, FLT3-ITD constructs (W51, NPOS, W78),
FLT3-TKD constructs (D835Y, D835V) or one of the
FLT3-JM-PM mutants (FLT3-V592A, FLT3-V579A, FLT3-
F594L, and FLT3-F590GY591D) were seeded at a den-
sity of 4  104 cells/mL in the absence or presence of
IL-3. Viable cells were counted after 72 hours. The
growth of cells in the presence of IL-3 was defined as
100% (control). All FLT3-JM-PM mutants showed a
significantly higher proliferation rate compared with
FLT3-WT (*P  .05), although not as high as FLT3-ITD or
FLT3-TKD. SD is indicated. (B) FLT3-WT and mutant-
expressing Ba/F3 cells were seeded at a density of
4  104 cells/mL in the absence or presence of human
recombinant FL (50 ng/mL). Viable cells were counted
after 72 hours by trypan blue exclusion. The cell number
of FLT3-WT cells after 72 hours was defined as 100%.
SEM is indicated.
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48 hours, respectively. In contrast, only 11% to 15% (24 hours) and
25% to 49% (48 hours) apoptotic cells were found in FLT3-JM-PM–
expressing cells. Addition of IL-3 protected all cell lines from
undergoing apoptosis (data not shown).
In summary, these data clearly show that the point mutations
in JM of FLT3 constitutively activate antiapoptotic signaling
pathways of FLT3, although the antiapoptotic activity of these
mutants is significantly lower compared with FLT3-ITD and
FLT3-TKD mutants.
FLT3-JM-PM receptors are constitutively autophosphorylated
on tyrosine residues
We next examined whether the acquisition of point mutations in the
JM domain of FLT3 results in constitutive activation of the FLT3
receptor. Cell lysates of unstimulated and FL-stimulated FLT3-JM-
PM–expressing Ba/F3 cells as well as FLT3-ITD– and FLT3-TKD–
expressing cells were prepared and subjected to immunoprecipita-
tion with FLT3 antibody followed by immunoblotting with anti–
phospho-tyrosine antibody. In contrast to the FLT3-WT receptor,
all FLT3-JM-PM receptors were constitutively phosphorylated on
tyrosine residues (Figure 4A).
Densitometric analysis revealed that the ratios of phosphory-
lated to total FLT3-JM-PM receptors were 20% for FLT3-V592A–
expressing cells, 28% for FLT3-V579–expressing cells, 10% for
FLT3-F594L–expressing cells, and 14% for FLT3-F590GY591D–
expressing cells, and considerably lower compared with the ratio of
phosphorylated FLT3-ITD (42%-60%) and FLT3-TKD (41%-
66%) receptors (Figure 4B). We further performed cross-linking
experiments to analyze constitutive oligomerization of FLT3-
JM-PM receptors. Unstimulated and FL-stimulated cells were
incubated in bis(sulfosuccinimidyl)suberate (BS3) cross-linking
buffer for 30 minutes before cell lysis. In the absence of FLT3
ligand, FLT3-JM-PM receptors showed a higher rate of constitutive
oligomerization compared with FLT3-WT receptors (data not shown).
Taken together, the acquisition of FLT3-JM-PMs leads to direct
activation of the receptor. FLT3-JM-PMs show increased autophos-
phorylation and constitutive oligomerization in the absence of
FLT3 ligand. The extent of receptor activation is nevertheless
weaker compared with FLT3-ITD and FLT3-TKD receptor mutants.
FLT3-JM point mutants induce constitutive STAT5 activation
STAT5 is an important downstream target of the constitutively
activated FLT3 receptor and is probably responsible for most of its
transforming potential in vitro and in vivo.15,20,23 Activation of
STAT5 results in altered expression of several genes regulating cell
cycle, apoptosis, and proliferation.24 To investigate the activation
of the STAT5 signaling pathway, we prepared crude cell lysates of
serum-starved Ba/F3 cells transduced with either FLT3-WT, FLT3-
JM-PM (FLT3-V592A, FLT3-V579A, FLT3-F594L, and FLT3-
F590GY591D) or FLT3-ITD/FLT3-TKD constructs. Lysates were
analyzed by immunoblotting with a specific antibody against
phospho-STAT5. We could clearly demonstrate that the expression
of FLT3-JM-PMs in Ba/F3 cells induces a significantly stronger
STAT5 activation compared with FLT3-WT (Figure 5A). The ratio
of phosphorylated STAT5 to total STAT5 in FLT3-JM-PM cells
ranged from 20% to 35% and was considerably weaker than in
FLT3-ITD–expressing cells (49%-61%) and FLT3-TKD–
expressing cells (56%-66%) (Figure 5B). We further investigated
Figure 3. Point mutations in the JM domain of FLT3
induce resistance to apoptosis after IL-3 withdrawal.
(A) Ba/F3 cells stably transduced with FLT3-WT, FLT3-
ITD (W51, NPOS, W78), FLT3-TKD (D835Y, D835V) or
FLT3-JM-PM (FLT3-V592A, FLT3-V579A, FLT3-F594L,
and FLT3-F590GY591D) were seeded at a density of
1  105 cells/mL and grown for 48 hours in the presence
or absence of IL-3. Cells were then analyzed by flow
cytometry after staining with annexin V–PE and 7-AAD.
All FLT3-JM-PMs showed a significantly lower percent-
age of apoptotic cells compared with FLT3-WT after IL-3
withdrawal (*P  .05). FLT3-ITDs and FLT3-TKDs pro-
tected cells from undergoing apoptosis. (B) Cells were
cultured in the presence or absence of IL-3 for 24 hours
and analyzed by flow cytometry after staining of nuclei
with propidium iodide. FLT3-JM-PMs showed a signifi-
cantly lower percentage of hypodiploid nuclei compared
with FLT3-WT (*P  .05). SD is indicated.
Figure 4. FLT3-JM-PM receptors are constitutively autophosphorylated on
tyrosine residues. (A) Lysates of FL-stimulated (100 ng FL /mL for 5 minutes) and
unstimulated, serum-starved FLT3-WT–expressing cells, FLT3-JM-PM–expressing
cells (FLT3-V592A, FLT3-V579A, FLT3-F594L, and FLT3-F590GY591D), and FLT3-
W51–expressing cells were subjected to immunoprecipitation with FLT3 antibody
followed by immunoblotting with phospho-tyrosine antibody. Blots were stripped and
reblotted with FLT3-antibody. (B) FLT3-ITD–expressing cells (W51, NPOS, and W78)
and FLT3-TKD–expressing cells (D835Y and D835V) were analyzed as described in
panel A and densitometric analysis was performed using TINA 2.0 software to
quantify the percentage of phospho-FLT3 of total FLT3.
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the FL-independent activation of MAP kinase (MAPK) and the
activation of serine/threonine protein kinase AKT as a marker for
activation of phosphatidylinositol 3-kinase (PI3K)–dependent path-
ways. Immunoblotting with phospho-AKT-Ser473–specific anti-
body revealed a slightly increased basal level of phosphorylation of
AKT in FLT3-JM-PM cells compared with FLT3-WT (data not
shown). Immunoblotting with phospho-MAPK antibody showed
the same level of phosporylation of MAPK in FLT3-JM-PM cells
as in FLT3-WT cells (data not shown). Since AKT activation is
only slightly increased in FLT3-JM-PM cells and MAPK activation
level is not changed compared with FLT3-WT, we conclude that
the prominent proliferative signal is mediated by STAT5.
As the JM point mutants induce antiapoptotic signaling when
expressed in Ba/F3 cells, we hypothesized that this might be due to
the up-regulation of an important STAT5 antiapoptotic downstream
target, Bcl-x(L). Cell lysates were subjected to Western blot analysis and
immunoblotted with specific monoclonal antibody against Bcl-x(L). We
found a significant up-regulation of Bcl-x(L) in FLT3-V592A–, FLT3-
V579A–, FLT3-F594L–, and FLT3-F590GY591D–expressing cells
compared with FLT3-WT (Figure 5C).
Thus, the most important signaling pathway downstream of FLT3,
STAT5, is constitutively activated by the FLT3-V592A, FLT3-V579A,
FLT3-F594L, and FLT3-F590GY591D receptor mutants and induces
up-regulation of the antiapoptotic protein Bcl-x(L).
The FLT3 PTK inhibitor PKC412 induces growth arrest and
inhibits tyrosine phosphorylation of STAT5 in FLT3
JM point mutants
PKC412 was inititally developed as a vascular endothelial growth
factor receptor (VEGFR) inhibitor and was shown to block the
activity of FLT3-WT and mutant FLT3 receptors.25,26 To analyze
the inhibitory activity of PKC412 against FLT3-JM-PMs, we
treated the FLT3-V592A–, FLT3-V579A–, FLT3-F594L–, and
FLT3-F590GY591D–expressing cells with different concentra-
tions of PKC412 up to 50 nM. PKC412 showed a strong growth
inhibitory effect on FLT3-V592A–, FLT3-V579A–, FLT3-F594L–,
and FLT3-F590GY591D receptor–expressing cells in the absence
but not in the presence of IL-3. The inhibitory concentration of
50% (IC50) of PKC412 was significantly lower in FLT3-JM-PM–
expressing cells ( 1 nM) and FLT3-D835Y–expressing cells
( 1 nM) compared with the FLT3-W51 mutant (5 nM; Table 1).
Furthermore, we treated serum-starved FLT3-V592A–, FLT3-
V579A–, FLT3-F594L–, FLT3-F590GY591D–, and FLT3-W51–
expressing cells for 1 hour with 50 nM PKC412. Immunoblotting
with pSTAT5 antibody showed a significant reduction in the
amount of phosphorylated STAT5 in FLT3-V592A, FLT3-V579A,
FLT3-F594L, FLT3-590G591D, and FLT3-W51, confirming that
STAT5 activation is directly mediated by the activated FLT3
receptor (Figure 6).
These data clearly show that the proliferative signal of FLT3-
JM-PM receptors can be blocked by PKC412 and that FLT3-JM-
PM–expressing cells are considerably more sensitive to this
compound than FLT3-ITD–expressing cells.
Discussion
Since 1996, when the first description of activating FLT3 mutations
was published, extensive research has been performed to character-
ize the functional relevance of these mutations in AML.3 Although
the FLT3 gene has been studied in detail in AML, we and others
were recently able to identify a new class of mutations in patients
with AML, the FLT3-JM-PMs.15,16 According to Stirewalt et al,16
who performed a SSCP analysis of the entire JM region, the
frequency of these point mutations in the JM region was about 2%.
Figure 5. FLT3-JM-PM mutants expressed in Ba/F3 cells show constitutive
activation of STAT5 and up-regulation of Bcl-x(L). (A) FLT3-WT, FLT3-W51,
FLT3-V592A, FLT3-V579A, FLT3-F594L, FLT3-F590GY591D, or mock-transduced
cells were starved for 24 hours in the presence of 0.3% FBS and stimulated with 100
ng FL /mL for 5 minutes. Crude-cell lysates were separated by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and blotted on a nitrocellu-
lose membrane. Blots were incubated with anti–phospho-STAT5 antibody, stripped,
and reblotted with anti-STAT5 antibody. (B) FLT3-ITD–expressing cells (W51, NPOS,
and W78) and FLT3-TKD–expressing cells (D835Y and D835V) were analyzed as
described in panel A, and the films were subjected to densitometric analysis to
quantify the percentage of phospho-STAT5 in relation to total STAT5 amount in
unstimulated cells. (C) Crude-cell lysates were subjected to Western blot analysis
using a monoclonal antibody against Bcl-x(L). Bcl-x(L) overexpressed in Ba/F3 cells
served as a positive control. Equal protein loading in all lanes was confirmed by
immunoblotting using an anti–-actin antibody.
Table 1. FLT3 JM point mutants expressed in Ba/F3 cells are
sensitive to the FLT3 PTK inhibitor PKC412
Mutation class IC50 PKC412, nM
FLT3-ITD
W51 5.0
FLT3-TKD
D835Y 0.8
FLT3-JM-PM
V592A 0.7
V579A 0.8
F594L 0.9
F590GY591D 0.7
FLT3-WT, FLT3-W51, FLT3-D835Y, and the FLT3-JM-PM mutants FLT3-V592A,
FLT3-V579A, FLT3-F594L, and FLT3-F590GY591D expressing Ba/F3 cells were
seeded at a density of 4  104 cells/mL in the absence or presence of different
concentrations of PKC412 (0 to 50 nM) and counted after 72 hours. All cell lines were
also cultured in the presence of IL-3 and 50 nM PKC412 to confirm nontoxicity of
PKC412 to Ba/F3 cells. The IC50 was calculated from three independent experi-
ments.
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In the present study, we focused mainly on the V592A mutation
that we found in MM-1 and MM-6 cell lines. Our LightCycler-
based screening assay covers approximately 5 to 6 amino acids
surrounding V592A and underestimates the frequency of FLT3-
PMs in the JM domain.
Our results show that these JM point mutations in the FLT3
gene induce factor-independent growth and hyperresponsiveness to
FL, and have an antiapoptotic activity in hematopoietic cells. The
FLT3-JM-PM receptors are autophosphorylated and show a higher
constitutive oligomerization rate compared with FLT3-WT recep-
tors. We could show that all FLT3-JM-PMs activate STAT5 and
up-regulate Bcl-x-(L). The activation of the receptor and STAT5,
respectively, is lower in FLT3-JM-PM–expressing cells compared
with FLT3-ITD– and FLT3-TKD–expressing cells, and we propose
that these differences are mainly responsible for the weaker
phenotype of FLT3-JM-PMs. A selective FLT3 PTK inhibitor,
PKC412, was able to abrogate the factor-independent growth and
down-regulated the activation of STAT5. Compared with the two
known classes of FLT3 mutations (FLT3-ITD and FLT3-TKD),
FLT3-JM-PM–expressing cells showed a weaker phenotype in
terms of their proliferation rate, antiapoptotic activity, FLT3
receptor activation, and activation of STAT5 (summarized in
Table 2).
The reason for the weaker transforming potential might be that
the FLT3-JM-PMs, in contrast to FLT3-ITDs, induce only subtle
alterations in the protein structure of the autoinhibitory JM domain.
All FLT3-JM-PM–expressing cells showed hyperresponsiveness to
FLT3 ligand, with a 2 to 4 times higher proliferation rate compared
with FL-stimulated FLT3-WT cells. As FLT3 ligand is often
coexpressed in primary AML blast cells, this might reflect more
precisely the “in vivo” situation. Furthermore, we could demon-
strate that a single point mutation in the JM domain is sufficient to
constitutively activate the receptor and increase its spontaneous
dimerization rate.
STAT5, the most important downstream target of FLT3, is
strongly associated with tumor development and progression.27 For
example, it directly induces the expression of antiapoptotic pro-
teins, like Bcl-x(L), which play an essential role in resistance
against apoptotic cell death.28,29 Bcl-x(L) is overexpressed in a high
percentage of blast cells from patients with AML and confers a
poor prognosis in these patients.30 Our results clearly show that
FLT3-JM-PMs activate STAT5 and induce up-regulation of Bcl-
x(L), and suggest that this pathway is critical for the transforming
capacity of activated FLT3 mutants.
The success of the small-molecule tyrosine-kinase inhibitor
imatinib (Novartis) in the treatment of chronic myelogenous
leukemia (CML) has given much encouragment for the develop-
ment of other molecularly targeted cancer therapeutics. Due to the
fact that FLT3 is one of the most frequently mutated genes in AML,
it is a promising target for the treatment of AML. Small-molecule
FLT3 PTK inhibitors have been developed, and are able to induce
apoptosis in cell lines with FLT3-activating mutations and prolong
the survival of mice expressing mutant FLT3.31-34 We analyzed the
inhibitory activity of PKC412, a compound which is now tested in
phase 2 clinical trials in AML, on Ba/F3 cells expressing FLT3-
V592A, FLT3-V579A, FLT3-F594L, FLT3-F590GY591D, FLT3-
W51, and FLT3-D835Y. Our data clearly show that FLT3-JM-PM–
induced cell growth can be inhibited by PKC412. In addition, we
were able to show down-regulation of autoactivated STAT5 after
treating cells with PKC412, providing direct evidence for the
efficacy of this compound to abrogate mitogenic signaling path-
ways of the receptor. Moreover, the FLT3-JM-PMs are consider-
ably more sensitive to PKC412 than FLT3-ITDs, suggesting that
patients with JM point mutations in FLT3 should respond to even
lower doses of PKC412.
Our results show that a single amino acid change in the
autoinhibitory JM domain is sufficient to activate the transforming
potential of FLT3. To structurally analyze the putative effect of the
point mutations, we mapped the mutations on the crystal structure
of the FLT3 JM domain (Figure 7).10 From the FLT3 crystal
structure it is obvious that these point mutations cluster at a core
interaction site of the JM domain with the remainder of the
molecule. It is therefore likely that these mutations reduce the
stability of the JM domain in the autoinhibitory conformation. For
instance, F594 and V592 together form a small hydrophobic
contact face of the JM domain with the kinase domain. F594L and
V592A mutations topologically perturb this hydrophobic contact
face, likely resulting in a destabilized interface between JM domain
and kinase domain. Likewise, mutations of F590 to glycine and of
Y591 to aspartate might destabilize the autoinhibitory conforma-
tion of the JM domain by adding more backbone flexibility, but also
by removing the stabilizing contacts of the tyrosine side chain with
the rest of the molecule. The effect of Y591D on the activity of the
molecule is also consistent with the idea that phosphorylation of the
tyrosine pair Y589 and Y591 sterically prohibits the observed
autoinhibitory conformation of the JM domain. Finally, V579
stabilizes the inserted  strand of JM-B by a hydrophobic
interaction with the rest of the molecule. This stabilization is likely
Figure 6. PKC412 inhibits autophosphorylation of STAT5 in Ba/F3 cells
expressing JM point-mutated FLT3 receptors. Mock cells and cells expressing
FLT3-WT, FLT3-W51, FLT3-V592A, FLT3-V579A, FLT3-F594L, and FLT3-
F590GY591D were starved for 24 hours and treated with 50 nM PKC412 1 hour
before cell lysis. Cell lysates were subjected to Western blot analysis using polyclonal
anti–phospho-STAT5 antibody. Blots were stripped and reblotted with polyclonal
anti-STAT5 antibody.
Table 2. Comparison of the phenotype of FLT3-JM-PM– to FLT3-ITD/TKD–expressing Ba/F3 cells
FLT3-WT FLT3-ITD FLT3-TKD FLT3-JM-PM
IL-3-independent proliferation*    
Antiapoptotic activity†    
Receptor autophosphorylation‡    
STAT5 autoactivation§    
* indicates 80%-100%; , 50%-79%; , 5%-49%; and , less than 5% viable cells in percentage of IL-3 growth after 72 hours (Figure 2A).
† indicates less than 10%; , 10%-24%; , 25%-50%; and , more than 50% apoptotic cells after 48 hours (Figure 3A).
‡ indicates more than 70%; , 40%-70%; , 10%-39%; and , less than 10% phospho-FLT3 of total FLT3 (Figure 4B).
§ indicates 50% or more; , 36%-49%; , 16%-35%; and , 15% or less phospho-STAT5 of total STAT5 (Figure 5B).
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reduced by mutating this residue to alanine, which would create a
cavity in the molecule. Taken together, the effect of the JM-PMs
supports a model in which the JM domain rearranges upon
activation of the kinase. This rearrangement could be normally
promoted by phosphorylation of Y589 and Y591, but in the case of
activating mutations, also by destabilization of the autoinhibitory
conformation of the JM domain. In this respect, the mutations
might promote tyrosine phosphorylation by rendering the JM
domain more accessible for autophosphorylation.
The FLT3-ITDs, which are primarily located in the JM-Z
region, confer a strong transforming potential to hematopoietic cell
lines, but the mechanisms by which these duplicated sequences of
FLT3-ITD mutants change the conformation of the FLT3 protein
structure remain unknown. It was proposed that the increased
length of the JM-Z offsets the position of JM-S, likely disturbing
the ideal orientation of JM-S to position JM-B in its binding site.10
It is difficult to say what effect a length increase in JM-Z has on the
overall integrity of the protein structure, but the close location to
JM-B suggests that these mutations might completely prevent
formation of an autoinhibitory state. From a structural point of
view, the presence of additional residues in JM-Z could easily
prevent the formation of structurally observed folds of JM-S in the
autoinhibitory state. Although FLT3-ITDs can involve the same
amino acids in the JM domain as those affected by point mutations,
they probably alter the protein conformation in a different way.
Compared with FLT3-ITDs, the point mutations represent a much
more subtle change in the structural chemistry of this region and
might still allow formation of an autoinhibitory complex, albeit
with reduced stability. A full (FLT3-ITD) versus partial (FLT3-
JM-PM) interference with the autoinhibitory state could explain
the much stronger phenotype of ITD mutations compared with
point mutations.
The cytoplasmatic juxtamembrane domain is highly conserved
between different members of class III receptor tyrosine kinases. A
variety of malignancies have been described which harbor activat-
ing mutations in the juxtamembrane domain of KIT.11-14,35-37 In
10% to 20% of all gastrointestinal tumors (GISTs), gain-of-
function single amino acid substitutions of the JM region were
reported, and two possible hotspot regions, comprising codons 550
to 560 and 567 to 576, were suggested.38,39 Among others, one
frequently affected position is KIT-V560. This residue is homolo-
gous to V579 in FLT3 that was found to be mutated in one AML
patient (FLT3-V579A). Furthermore the second region, aa 567 to
576 in KIT, is partially homologous to FLT3 and comprises all
other 3 reported point mutations (FLT3-V592A, FLT3-
F590GY591D, and FLT3-F594L). The clustering of these muta-
tions in the JM domains of both KIT and FLT3 supports their
specific biological significance. Further confirmation on the func-
tional relevance of the JM domain was provided by 2 investigators
who performed a detailed mutational screening.40,41 Ma et al40
analyzed the region from M552 to I563 in the JM of the KIT
receptor, and Irusta et al41 analyzed the region from R529 to W561
in JM of platelet-derived growth factor receptor  (PDGFR).
Single amino acids were mutated to alanine, and the constitutive
tyrosine phosphorylation of the receptor was analyzed by both
groups. The V560A mutation in KIT, homologous to V579A in
FLT3, as well as V550A mutation in PDGFR, homologous to
V592A in FLT3, resulted in autophosphorylation of the receptor.
Mutation of I537A and D551A in PDGFR, corresponding to
FLT3 positions V579 and F594, displayed a strong and weak
autophosphorylation, respectively. These results clearly show that point
mutations targeting this region lead to destabilization of the autoinhibi-
tory JM conformation and finally to activation of the receptor.
In conclusion, we were able to define a new class of activating
FLT3 mutations, point mutations that cluster in the JM region. The
FLT3-JM-PMs confer a transforming potential to hematopoietic
cells in vitro that was weaker than that of FLT3-ITD and
FLT3-TKD mutant receptors. Our data suggest that patients
carrying FLT3-JM-PMs might respond to treatment with selective
FLT3 inhibitors.
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Transformation by oncogenic mutants and ligand dependent 
activation of FLT3-WT requires the tyrosine residues 589 and 591 
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ABSTRACT 
Mutations in the protein tyrosine kinase FLT3 can be found in 30% of AML patients 
and are associated with an inferior prognosis. To characterize the critical domains 
and residues of active FLT3 receptor mutants, we performed a detailed structure-
function analysis of putative auto-phosphorylation tyrosine (Y) residues in the FLT3-
D835Y background. For this purpose, all Y residues in the juxtamembrane domain 
(Y566, Y572, Y589, Y591, Y597, and Y599), interkinase domain (Y726, Y768) and 
carboxyl terminus (Y955, Y969) of the FLT3-D835Y construct were successively 
mutated to Phenylalanine (F) and the transforming activity of these mutants was 
analyzed in IL-3-dependent Ba/F3 cells. The mutation of all these Y residues resulted 
in complete loss of the transforming potential of FLT3-D835Y, which further can be 
attributed to complete loss of STAT5 activation at molecular level. Re-introduction of 
single Y residues revealed the critical role of Y589 and Y591 in reconstituting IL-3 
independent growth of FLT3-TKD. Combined mutation of Y589 and Y591 to F also 
completely abrogated ligand-dependent stimulation of FLT3 wild type and the 
transforming activity and STAT5 activation of FLT3-ITD constructs. In summary, our 
study underlines the relevance of distinct Y residues for the mutated and wild type 
FLT3 receptor. 
